Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use

ABSTRACT

Substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines, compositions comprising them and use. The present invention relates in particular to novel substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines having therapeutic activity, which can be used in particular in oncology.

The present invention relates to novel chemical compounds, particularly novel tetrahydro-1H-pyrazolo[3,4-c]pyridines, compositions comprising them, and to their use as medicinal products.

More particularly, the invention relates to novel tetrahydro-1H-pyrazolo-[3,4-c]pyridines exhibiting anticancer activity, and in particular kinase-inhibiting activity, especially Tie2-inhibiting activity.

Only a few tetrahydro-1H-pyrazolo[3,4-c]pyridines are known.

Thus, WO 02/012442 discloses tetrahydro-1H-pyrazolo[3,4-c]pyridines substituted in the 5-position with an optionally substituted amino group. These products are useful in the treatment of cancer and of other diseases related to cell proliferation.

P. Krogsgaard-Larsen et al. in Eur. J. Med. Chemical—Chim. Ther. (1979), 14(2), p. 157-164, discloses two tetrahydro-1H-pyrazolo[3,4-c]pyridines substituted in the 3-position with a hydroxyl group.

WO 96/12720 claims tetrahydro-1H-pyrazolo[3,4-c]pyridines substituted in the 3-position with substituents chosen from H, alkyl, alkylene, cycloalkyl and methylenecycloalkyl, and in the 1- and 6-positions with varied substituents. These products are described as inhibitors (i) of phosphodiesterase type IV (PDE-IV), and (ii) of tumour necrosis factor (TNF), and are, as a result, considered to be useful in the treatment of inflammatory diseases. No example of a compound according to the invention is disclosed.

Attempts to obtain effective inhibitors of Tie2 have already been successful in the past (in this respect, see, for example, WO 98/02434; WO 98/41525; WO 99/10325; WO 99/17770; WO 99/54286; WO 99/21859; WO 99/55335; WO 00/17202; WO 00/17203; WO 00/27822; WO 00/75139; WO 01/37835; WO 01/57008; WO 01/72751; WO 02/060382; WO 02/076396; WO 02/076463; WO 02/076954; WO 02/076984; WO 02/076985; WO 02/080926; WO 03/004488).

However, none of those documents discloses 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine derivatives as defined below, exhibiting activity against kinases, in particular Tie2.

To this effect, the products in accordance with the invention, according to its first aspect, satisfy formula (I) below:

and its tautomers, in which:

-   L is chosen from a bond, CH₂, CO, SO₂, CONH, COO, NHCO, NH, NHSO₂,     SO₂NH, NHCONH, CH₂NH and NHCH₂, -   X is chosen from a bond, CH₂, CO, SO₂, CONH and COO; -   R1 is chosen from OH, H, alkyl, cycloalkyl, heterocyclyl, aryl,     heteroaryl, which is optionally substituted, and, when X is a bond,     then R1 may also be halogen; -   R2 is H or is chosen from alkyl, alkylene, cycloalkyl, heterocyclyl,     aryl, heteroaryl, which is optionally substituted;     the substituents being chosen independently from R3, O—R3, halogen,     NO₂, SO₂—R3, CO—R3, SO₂NH—R3, CONH—R3, N—(R3)₂, NHCO—R3, NHSO₂—R3,     NHCONH—R3, NHSO₂NH—R3, OCO—R3, COO—R3, OSO₂—R3, SO₂O—R3, OCONH—R3     and OSO₂NH—R3, where each R3 is chosen independently from H, alkyl,     cycloalkyl, alkenyl, aryl, heteroaryl, heterocyclyl, which is     optionally substituted with halogen, aryl, heteroaryl, R4, OR4 or     N(R4)₂, each R4 being chosen independently from H, C₁-C₄ alkyl and     halogenated C₁-C₄ alkyl.

Products in accordance with the invention, according to its first aspect, are more particularly chosen from products of formula (II) below:

and its tautomers, in which:

-   X is chosen from a bond, CH₂, CO, SO₂, CONH and COO; -   R1 is chosen from alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl,     which is optionally substituted; -   R2 is H or is chosen from alkyl, alkylene, cycloalkyl, heterocyclyl,     aryl, heteroaryl, which is optionally substituted;     the substituents being chosen independently from R3, O—R3, halogen,     NO₂, SO₂—R3, CO—R3, SO₂NH—R3, CONH—R3, N—(R3)₂, NHC0—R3, NHSO₂—R3,     NHCONH—R3, NHSO₂NH—R3, OCO—R3, COO—R3, OSO₂—R3, SO₂O—R3, OCONH—R3     and OSO₂NH—R3, where each R3 is chosen independently from H, alkyl,     cycloalkyl, alkenyl, aryl, heteroaryl, heterocyclyl, which is     optionally substituted with halogen, aryl, heteroaryl, OR4 or     N(R4)₂, where each R4 is chosen independently from H and C₁-C₄     alkyl.

Products in accordance with the invention, according to its first aspect, are more particularly chosen from products of formula (III) below:

and its tautomers, in which:

-   X is chosen from a bond, CH₂, CO, SO₂, CONH and COO; R1 is chosen     from alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, which is     optionally substituted; -   R2 is H or is chosen from alkyl, alkylene, cycloalkyl, heterocyclyl,     aryl, heteroaryl, which is optionally substituted;     in which the substituents are chosen independently from R3, O—R3,     halogen, NO₂, SO₂—R3, CO—R3, SO₂NH—R3, CONH—R3, N—(R3)₂, NHCO—R3,     NHSO₂—R3, NHCONH—R3, NHSO₂NH—R3, OCO —R3, COO—R3, OSO₂—R3, SO₂O—R3,     OCONH—R3 and OSO₂NH—R3, in which each R3 is chosen independently     from H, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, heterocyclyl,     which is optionally substituted with halogen, aryl, heteroaryl, OR4     or N(R4)₂, and in which each R4 is chosen independently from H and     C₁-C₄ alkyl.

A product in accordance with the invention is advantageously chosen from the products according to its first aspect, in which R1 is heteroaryl, which is optionally substituted, in which a preferred heteroaryl is chosen from benzimidazolyl, indolyl, pyrrolyl, optionally substituted with halogen, R4 or O—R4.

More particularly, a preferred heteroaryl is chosen from benzimidazol-2-yl, indol-2-yl, pyrrol-2-yl, optionally substituted with halogen, R4 or O—R4.

A product in accordance with the invention according to its first aspect advantageously has a substituent R2 chosen from phenyl, pyridyl, thienyl, C₁-C₄ alkyl, and C₃-C₇ cycloalkyl, which is optionally substituted.

X may advantageously be chosen from CO and SO₂.

A product in accordance with the invention according to its first aspect is advantageously chosen from the products of formula (I) in which R1 is H.

A preferred product is advantageously chosen from the products of formula (I) in which R1 is substituted aryl.

According to a first preferred embodiment, a preferred product is advantageously chosen from the products of formula (I) in which R1-L is R1-NH—CO, and more preferably when R1 is H.

Very preferably, and according to a second preferred embodiment, a preferred product is advantageously chosen from (i) the products of formula (I), or (ii) preferably the products according to the first preferred embodiment, in which X is a bond, and in which R2 is chosen from substituted aryl and substituted heteroaryl.

According to a third preferred embodiment, a more preferred product is chosen from the products in accordance with the invention according to its second embodiment, in which R2 is chosen from:

-   -   aryl substituted with NHSO₂—R3 or NHCONH—R3, and     -   heteroaryl substituted with NHSO₂—R3 or NHCONH—R3.

Products according to the third preferred embodiment are advantageously chosen from:

-   -   aryl substituted with NHSO₂—R3 or NHCONH—R3, and     -   heteroaryl substituted with NHSO₂—R3 or NHCONH—R3,         in which aryl is phenyl and in which heteroaryl is chosen from         pyridyl and pyrimidyl.

According to a fourth embodiment, products according to the third preferred embodiment are advantageously chosen from:

-   -   aryl substituted with NHSO₂—R3 or NHCONH—R3, and     -   heteroaryl substituted with NHSO₂—R3 or NHCONH—R3,         in which R3 is chosen from substituted aryl and substituted         heteroaryl, in which R3 is advantageously substituted with a         substituent selected from the group consisting of halogen, R4,         OR4 and N(R4)₂, in which each R4 is chosen independently from H,         C₁-C₄ alkyl and halogenated C₁-C₄ alkyl.

According to a fifth embodiment, products according to the fourth preferred embodiment are advantageously chosen from:

A product in accordance with the invention according to its first aspect may be in:

-   -   1) racemic form, or     -   2) a form enriched in a stereoisomer, or     -   3) a form enriched in an enantiomer; and may optionally be         salified.

According to a second aspect, the invention relates to pharmaceutical compositions comprising a product as defined above, in combination with a pharmaceutically acceptable excipient.

According to a third aspect, the invention relates to the use of a product as defined above, as an agent for modulating the activity of a kinase. A preferred kinase will advantageously be chosen from Tie2 and KDR. Tie2 is more preferred.

According to its third aspect, the invention relates to the use of a product as defined above, for producing a medicinal product that is useful for treating a pathological condition, in particular cancer.

Products in accordance with the invention can be obtained by methods well known to those skilled in the art, in particular as regards the techniques of coupling between an acid and an amine; see, for example, J. March, Advanced organic chemistry, (J. Wiley & Sons, ed.), fourth edition, 1992.

The products of the invention are useful as agents which inhibit a reaction catalysed by a kinase. Tie2 is a kinase for which the products of the invention will be particularly useful as inhibitors. These products can also be used as inhibitors of other kinases, such as KDR.

Reasons for which the kinases are chosen are given below:

Tie2

Tie-2 (TEK) is a member of a family of tyrosine kinase receptors specific for endothelial cells. Tie2 is the first receptor with tyrosine kinase activity for which both the agonist (angiopoietin 1 or Ang1), which stimulates autophosphorylation of the receptor and cell signalling [S. Davis et al (1996) Cell 87, 1161-1169] and the antagonist (angiopoietin 2 or Ang2) [P.C. Maisonpierre et al. (1997) Science 277, 55-60] are known. Angiopoietin 1 can synergize with VEGF in the final stages of neoangiogenesis [AsaharaT. Circ. Res.(1998) 233-240]. Knockout experiments and transgenic manipulations of the expression of Tie2 or of Ang1 result in animals which exhibit vascularization defects [D. J. Dumont et al (1994) Genes Dev. 8, 1897-1909 and C. Suri (1996) Cell 87, 1171-1180]. The binding of Ang1 to its receptor results in autophosphorylation of the kinase domain of Tie2, which is essential for neovascularization and for the recruitment and the interaction of the vessels with pericytes and smooth muscle cells; these phenomena contribute to the maturing and the stability of the newly formed vessels [P. C. Maisonpierre et al (1997) Science 277, 55-60]. Lin et al (1997), J. Clin. Invest. 100, 8: 2072-2078 and Lin P. (1998) PNAS 95, 8829-8834, have shown inhibition of tumour growth and vascularization and a decrease in lung metastases during adenoviral infections or during injections of the Tie-2 (Tek) extracellular domain in breast tumour and melanoma xenograph models.

Tie2 inhibitors can be used in situations where neovascularization takes place inappropriately (i.e. in diabetic retinopathy, chronic inflammation, psoriasis, Kaposi's sarcoma, chronic neovascularization due to macular degeneration, rheumatoid arthritis, infantile haemoangioma and cancers).

KDR

KDR (Kinase insert Domain Receptor), also known as VEGF-R2 (Vascular Endothelial Growth Factor Receptor 2), is expressed only in endothelial cells. This receptor binds to the angiogenic growth factor VEGF and thus acts as a mediator to a transduction signal via the activation of its intracellular kinase domain. Direct inhibition of kinase activity of VEGF-R2 makes it possible to reduce the phenomenon of angiogenesis in the presence of exogenous VEGF (Vascular Endothelial Growth Factor) (Strawn et al., Cancer Research, 1996, vol. 56, p. 3540-3545). This process has been demonstrated in particular using VEGF-R2 mutants (Millauer et al., Cancer Research, 1996, vol. 56, p. 1615-1620). The VEGF-R2 receptor does not appear to have any function in adults other than that related to the angiogenic activity of VEGF. Consequently, a selective inhibitor of the kinase activity of VEGF-R2 should only show slight toxicity.

In addition to this central role in the dynamic angiogenic process, recent results suggest that VEGF expression contributes to the survival of tumour cells after chemotherapy and radiotherapy, emphasizing the potential synergy of KDR inhibitors with other agents (Lee et al. Cancer Research, 2000, vol. 60, p. 5565-5570).

Experimental Section

Method A: Analysis by LC/MS

The LC/MS analyses were carried out on a Micromass model LCT device connected to an HP 1100 device. The abundance of the products was measured using an HP G1315A diode array detector over a wavelength of 200-600 nm and a Sedex 65 light scattering detector. The mass spectra were acquired over a range of from 180 to 800. The data were analysed using the Micromass MassLynx software. Separation was carried out on a Hypersil BDS C18, 3 μm (50×4.6 mm) column, eluting with a linear gradient of from 5 to 90% of acetonitrile comprising 0.05% (v/v) of trifluoroacetic acid (TFA) in water comprising 0.05% (v/v) TFA, over 3.5 min at a flow rate of 1 ml/min. The total analysis time, including the period for re-equilibrating the column, is 7 min.

Method B: Purification by LC/MS:

The products were purified by LC/MS using a Waters FractionsLynx system composed of a Waters model 600 gradient pump, a Waters model 515 regeneration pump, a Waters Reagent Manager dilution pump, a Waters model 2700 auto-injector, two Rheodyne model LabPro valves, a Waters model 996 diode array detector, a Waters model ZMD mass spectrometer and a Gilson model 204 fraction collector. The system was controlled by the Waters FractionLynx software. Separation was carried out alternately on two Waters Symmetry columns (C₁₈, 5 μM, 19×50 mm, catalogue reference 186000210), one column undergoing regeneration with a 95/5 (v/v) water/acetonitrile mixture comprising 0.07% (v/v) of trifluoroacetic acid, while the other column was being used for separation. The columns were eluted using a linear gradient of from 5 to 95% of acetonitrile comprising 0.07% (v/v) of trifluoroacetic acid in water comprising 0.07% (v/v) of trifluoroacetic acid, at a flow rate of 10 ml/min. At the outlet of the separation column, one-thousandth of the effluent is separated by means of an LC Packing Accurate, diluted with methyl alcohol at a flow rate of 0.5 ml/min and sent to the detectors, in a proportion of 75% to the diode array detector and the remaining 25% to the mass spectrometer. The rest of the effluent (999/1000) is sent to the fraction collector, where the flow is discarded for as long as the mass of the expected product is not detected by the FractionLynx software. The molecular formulae of the expected products are supplied to the FractionLynx software, which actuates the collection of the product when the mass signal detected corresponds to the ion [M+H]⁺ and/or to [M+Na]⁺. In certain cases, depending on the results of the analytical LC/MS, when an intense ion corresponding to [M+2H]⁺⁺ was detected, the value corresponding to half the calculated molecular mass (MW/2) is also supplied to the FractionLynx software. Under these conditions, the collection is also actuated when the mass signal of the ion [M+2H]⁺⁺ and/or [M+Na+H]⁺⁺ are detected.

Method C: EI Analysis

The mass spectra were produced by electron impact (70 eV) on a Finnigan SSQ 7000 spectrometer.

Method D: NMR Analysis

The NMR spectra were produced on a Bruker Avance 300 spectrometer and a Bruker Avance DRX 400 spectrometer.

tert-Butyl 4-(diazoethoxycarbonylmethyl)-4-hydroxypiperidine-1-carboxylate

CAS Name d MM eq mmol g ml 1 79099- N-Boc- 199.25 1.00 50.19 10.00 07-3 piper- idinone 2 623-73- Ethyl 1.085 114.1 1.05 52.70 6.01 5.54 4 diazo- acetate 3 109-72- 1.6 M 1.60 80.30 50.19 8 BuLi hexane 4 108-18- Diiso- 0.720 101.19 1.60 80.30 8.13 11.29 9 propyl- amine 5 109-99- THE on 10 500 9 4′mole- vol. cular sieve 6 64-19-7 100% 1.050 60.05 5.00 250.94 15.07 14.35 AcOH

A freshly prepared solution of LDA (prepared by the dropwise addition, under an inert atmosphere at −78° C., of 50.19 ml of 1.6 M of BuLi in hexane to a solution of 11.29 ml of diisopropylamine in 200 ml of dry THF) is added dropwise, under an inert atmosphere at −78° C., onto 10.0 g of N-Boc-piperidinone in suspension and 5.54 ml of ethyl diazoacetate in 300 ml of dry THF. The mixture is stirred at −78° C. for 4 hours and is then decomposed at −78° C. with 14.35 ml of concentrated AcOH. The mixture obtained is left at ambient temperature overnight, and the solvent is then evaporated off under reduced pressure, to {fraction (1/10)} of its initial volume, diluted in diisopropyl ether, and washed 4 times with a saturated NaHCO₃ solution. The organic phase is dried over MgSO₄. The hydrated salt is removed by filtration and the dry filtrate is concentrated under reduced pressure so as to give 15.12 g of a viscous yellow oil. LC/MS: RT=2.84; [M+1]+=304.33. The product is used as it is for the subsequent step.

tert-Butyl 4-(diazoethoxycarbonylmethyl)-3,6-dihydro-2H-pyridine-1-carboxylate

GAS Name d MM eq mmol g ml 1 P-31391- 313.35  1 48.25 15.12 106-4 2 10025- POCl₃ 1.67 153.33  2 96.51 14.80 8.86 87-3 3 110-86- Pyridine 0.983 79.1 20 965.06 76.34 77.66 1 (4Å m.s.) 4 108-20- iPr₂O  5 250 3 vol 5 1310- 0.1 M 40  1 48.25 483 73-2 NaOH

78.0 ml of dry pyridine are added to a solution of 15.12 g of tert-butyl 4-(diazoethoxycarbonylmethyl)-4-hydroxypiperidine-1-carboxylate into 250 ml of iPr₂O. The mixture is cooled to −10° C. and 8.86 ml of POCl₃ are added slowly with vigorous stirring. The mixture is then left to return to ambient temperature for 12 hours with stirring. The reaction mixture is decomposed with 500 ml of a 0.1M NaOH solution, and is then extracted 3 times with EtOAc. The organic phase is washed with a saturated NaCl solution and dried over MgSO₄. The hydrated salt is removed by filtration and the dry filtrate is concentrated under reduced pressure to {fraction (1/10)} of its initial volume. LC/MS:RT=4.57; [M+1]+=296.31. The product is used as it is for the subsequent step.

6-tert-Butyl 3-ethyl 2,4,5,7-tetrahydropyrazolo[3,4-c]pyridyl-3,6-dicarboxylate

CAS Name d MM eq mmol mg ml 1 P-31391-120-4 285.35 1.0 48.25 2 108-83-3 PhMe 150

The solution of tert-butyl 4-(diazoethoxycarbonylmethyl)-3,6-dihydro-2H-pyridyl-1-carboxylate in Py/EtOAc obtained in the preceding step is added dropwise to 150 ml of toluene reflux. The azeotrope Py/PhMe is distilled at a rate equivalent to the rate of addition. One hour after the end of addition, the solution is left to cool to ambient temperature, the solvent is evaporated off under reduced pressure and the crude product obtained (15.05 g) is purified by flash chromatography (SiO₂, CH₂Cl₂/MeOH 1% NH₃7M(MeOH) 40:1 then 30:1 then 20:1). The solvent is evaporated off and 10.05 g (71% over 3 steps) of a black solid are obtained: LC/MS: RT=3.88; [M+1]+=296.27.

(tert-Butyl 2,4,5,7-tetrahydropyrazolo[3,4-c]pyridyl-6-carboxylate)-3-carboxylic Acid

Cas Name d MM eq mmol g ml 1 P-31391- 295.34 1.0 34.03 10.05 123-1 2 1310-66- LiOH.H₂O 41.96 1.1 37.43 1.57 3 3 67-56-1 MeOH 10 375 vol. 4 7732-18- H₂O 1 38 5 vol

1.57 g of LiOH and 38 ml of water are added to a solution of 10.05 g of 6-tert-butyl butyl 3-ethyl 2,4,5,7-tetrahydropyrazolo[3,4-c]pyridyl-3,6-dicarboxylate in 375 ml of MeOH. The mixture obtained is refluxed overnight. The solution is cooled to ambient temperature and is then acidified to pH=2 with 50 ml of a 1M HCl solution. The solution is then extracted 4 times with EtOAc. The organic phase is washed with a saturated NaCl solution and then dried over Na₂SO₄. The salt obtained is removed by filtration and the solvent is evaporated off under reduced pressure so as to produce 8.90 g (98%) of a white solid. LC/MS: RT=3.21; [M+1]+=268.23.

Preparation of a Library of Products:

tert-Butyl 3-(alkylcarbamoyl, arylcarbamoyl, heteroarylcarbamoyl, etc.)-2,4,5,7-tetrahydropyrazolo[3,4-c]pyridine-6-carboxylate

CAS Name d MM mmol g ml 1 P-31391-031-5 267.28 1.0 3.741 1.00 amine 2.0 6.744 2 538-75-0 DCC 206.33 1.0 3.741 0.772 3 2592-95-2 HOBt.H₂O 153.13 1.5 5.612 0.859 4 68-12-2 DMF 5   19 vol. General Method: DCC and HOBT.H₂O in solution in DMF with 2 eq of amine (R, Ar, or Het)-NH₂ are added to a solution of 1 eq of tert-butyl (2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridyl-6-carboxylate)-3-carboxylic acid in DMF and the mixture is stirred at ambient temperature for 3 h. The solvent is evaporated off under reduced pressure at 35° C. overnight. The crude product obtained is purified by flash chromatography (SiO₂, CH₂Cl₂/MeOH 1% NH₃7M_((MeOH)) 20:1 then 10:1 then 5:1, according to the products).

List of amines R1-NH₂ used (Table 1) [Comment: R1-NH₂═(R, Ar, or Het)—NH₂]: TABLE 1 Reference number of the amine Structure 1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

3-(Alkylcarbamoyl, arylcarbamoyl, heteroarylcarbamoyl, etc.)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-6-ium Trifluoroacetate

General Method:

16 eq of tert-butyl 3-(alkylcarbamoyl, arylcarbamoyl, heteroarylcarbamoyl, etc.)-2,4,5,7-tetrahydropyrazolo[3,4-c]pyridine-6-carboxylate in a 1:1 THF/water solution, and the solution is refluxed for 2 h. The solvent is evaporated off under reduced pressure and the viscous oil collected is dried under vacuum overnight. The product thus obtained is used without purification, in the subsequent step. 6-(Alkyl, aryl, heteroaryl, etc.)carbonyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4c]pyridiene-3-(alkyl, aryl, hetyl, etc.)amide

General Method:

A solution of 2.5 M HOBt.H₂O (2 eq) in DMF, a solution of 0.833M HBTU in DMF (2 eq), a solution of 2.5M DIPEA (4 eq) in DMF and a suspension or a solution at an appropriate concentration of an R₂COOH (2 eq) in DMF are added, in order, to a solution of 1 eq of 3-(alkylcarbamoyl, arylcarbamoyl, heteroarylcarbamoyl, etc.)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-6-ium trifluoroacetate in DMF. The solutions are stirred overnight at ambient temperature and are then acidified with 100 μl of 100% AcOH, filtered and purified by preparative LC/MS.

List of the acids R2 COOH used (Table 2): TABLE 2 Reference number of the acid Nomenclature 1 1-Phenyl-1-cyclopropylcarboxylic acid 2 Acetic acid 3 Propiolic acid 4 Crotonic acid 5 Vinylacetic acid 6 Pyruvic acid 7 Sarcosine 8 Methoxyacetic acid 9 Lactic acid 10 3,3-Dimethylacrylic acid 11 Cyclopropylacetic acid 12 Valeric acid 13 N,N-dimethylglycine 14 3-Mercaptopropionic acid 15 (Methylthio)acetic acid 16 Pyrrole-2-carboxylic acid 17 1-Cyanocyclopropanecarboxylic acid 18 2-Furoic acid 19 4-Pyrazolecarboxylic acid 20 Imidazole-4-carboxylic acid 21 1-Cyclopentenecarboxylic acid 22 Acid 23 Acetoxyacetic acid 24 Hydantoic acid 25 Benzoic acid 26 Nicotinic acid 27 2-Pyrazinecarboxylic acid 28 o-Toluic acid 29 Phenylacetic acid 30 Salicylic acid 31 2-Fluorobenzoic acid 32 3-Cyanobenzoic acid 33 4-Vinylbenzoic acid 34 2-Phenylpropionic acid 35 N-Methylanthranilic acid 36 2-Methoxybenzoic acid 37 2-Hydroxyphenylacetic acid 38 4-Hydroxymethylbenzoic acid 39 2-Fluorophenylbenzoic acid 40 2,6-Difluorobenzoic acid 41 Indole-3-carboxylic acid 42 3,5-Dimethylphenylacetic acid 43 3-(Dimethylamino)benzoic acid 44 Piperonylic acid 45 DL-tropic acid 46 3-Methoxyphenylacetic acid 47 3-Methoxysalicylic acid 48 4-(Methylthio)benzoic acid 49 2-Chlorophenylacetic acid 50 2-Naphthoic acid 51 2-Chloro-6-fluorobenzoic acid 52 1-Methylindole-3-carboxylic acid 53 3-Acetamidobenzoic acid 54 4-(Dimethylamino)salicylic acid 55 2,3-Dimethoxybenzoic acid 56 4-Chlorophenylpropionic acid 57 2-Chloromandelic acid 58 2-Chloro-6-fluorophenylacetic acid 59 1-Phenyl-1-cyclopentanecarboxylic acid 60 2,6-Dichlorobenzoic acid 61 3-Methyl-2-phenylvaleric acid 62 4-Phenylbenzoic acid 63 2-Chloro-4-nitrobenzoic acid 64 2-Benzylbenzoic acid 65 2-Phenoxybenzoic acid 66 2-Ethoxy-1-naphthoic acid 67 4-(4-N-Propylphenyl)benzoic acid 68 3,5-Dibromosalicylic acid 69 2,6-Dichlorophenylacetic acid 70 Cyanoacetic acid Results

The following products are prepared according to the process described above.

In order to simplify the representation of the products in Table 3 which follows, the pyrazolopiperidine ring presented in Scheme A is symbolized by the letter H, the amines R1-NH₂ which are linked to H are symbolized by the letter B followed by a number ranging from 1 to 15, corresponding to the products listed in Table 1, and the acids R2-COOH which are linked to H are symbolized by the letter A followed by a number from 1 to 70, corresponding to the products listed in Table 2.

Thus, a product referred to as A1-H-B1 corresponds to the following structure: TABLE 3

A1-H-B1 A2-H-B1 A3-H-B1 A4-H-B1 A5-H-B1 A6-H-B1 A7-H-B1 A1-H-B2 A2-H-B2 A3-H-B2 A4-H-B2 A5-H-B2 A6-H-B2 A7-H-B2 A1-H-B3 A2-H-B3 A3-H-B3 A4-H-B3 A5-H-B3 A6-H-B3 A7-H-B3 A1-H-B4 A2-H-B4 A3-H-B4 A4-H-B4 A5-H-B4 A6-H-B4 A7-H-B4 A1-H-B5 A2-H-B5 A3-H-B5 A4-H-B5 A5-H-B5 A6-H-B5 A7-H-B5 A1-H-B6 A2-H-B6 A3-H-B6 A4-H-B6 A5-H-B6 A6-H-B6 A7-H-B6 A1-H-B7 A2-H-B7 A3-H-B7 A4-H-B7 A5-H-B7 A6-H-B7 A7-H-B7 A1-H-B8 A2-H-B8 A3-H-B8 A4-H-B8 A5-H-B8 A6-H-B8 A7-H-B8 A1-H-B9 A2-H-B9 A3-H-B9 A4-H-B9 A5-H-B9 A6-H-B9 A7-H-B9 A1-H-B10 A2-H-B10 A3-H-B10 A4-H-B10 A5-H-B10 A6-H-B10 A7-H-B10 A1-H-B11 A2-H-B11 A3-H-B11 A4-H-B11 A5-H-B11 A6-H-B11 A7-H-B11 A1-H-B12 A2-H-B12 A3-H-B12 A4-H-B12 A5-H-B12 A6-H-B12 A7-H-B12 A1-H-B13 A2-H-B13 A3-H-B13 A4-H-B13 A5-H-B13 A6-H-B13 A7-H-B13 A1-H-B14 A2-H-B14 A3-H-B14 A4-H-B14 A5-H-B14 A6-H-B14 A7-H-B14 A1-H-B15 A2-H-B15 A3-H-B15 A4-H-B15 A5-H-B15 A6-H-B15 A7-H-B15 A8-H-B1 A9-H-B1 A10-H-B1 A11-H-B1 A12-H-B1 A13-H-B1 A14-H-B1 A8-H-B2 A9-H-B2 A10-H-B2 A11-H-B2 A12-H-B2 A13-H-B2 A14-H-B2 A8-H-B3 A9-H-B3 A10-H-B3 A11-H-B3 A12-H-B3 A13-H-B3 A14-H-B3 A8-H-B4 A9-H-B4 A10-H-B4 A11-H-B4 A12-H-B4 A13-H-B4 A14-H-B4 A8-H-B5 A9-H-B5 A10-H-B5 A11-H-B5 A12-H-B5 A13-H-B5 A14-H-B5 A8-H-B6 A9-H-B6 A10-H-B6 A11-H-B6 A12-H-B6 A13-H-B6 A14-H-B6 A8-H-B7 A9-H-B7 A10-H-B7 A11-H-B7 A12-H-B7 A13-H-B7 A14-H-B7 A8-H-B8 A9-H-B8 A10-H-B8 A11-H-B8 A12-H-B8 A13-H-B8 A14-H-B8 A8-H-B9 A9-H-B9 A10-H-B9 A11-H-B9 A12-H-B9 A13-H-B9 A14-H-B9 A8-H-B10 A9-H-B10 A10-H-B10 A11-H-B10 A12-H-B10 A13-H-B10 A14-H-B10 A8-H-B11 A9-H-B11 A10-H-B11 A11-H-B11 A12-H-B11 A13-H-B11 A14-H-B11 A8-H-B12 A9-H-B12 A10-H-B12 A11-H-B12 A12-H-B12 A13-H-B12 A14-H-B12 A8-H-B13 A9-H-B13 A10-H-B13 A11-H-B13 A12-H-B13 A13-H-B13 A14-H-B13 A8-H-B14 A9-H-B14 A10-H-B14 A11-H-B14 A12-H-B14 A13-H-B14 A14-H-B14 A8-H-B15 A9-H-B15 A10-H-B15 A11-H-B15 A12-H-B15 A13-H-B15 A14-H-B15 A15-H-B1 A16-H-B1 A17-H-B1 A18-H-B1 A19-H-B1 A20-H-B1 A21-H-B1 A15-H-B2 A16-H-B2 A17-H-B2 A18-H-B2 A19-H-B2 A20-H-B2 A21-H-B2 A15-H-B3 A16-H-B3 A17-H-B3 A18-H-B3 A19-H-B3 A20-H-B3 A21-H-B3 A15-H-B4 A16-H-B4 A17-H-B4 A18-H-B4 A19-H-B4 A20-H-B4 A21-H-B4 A15-H-B5 A16-H-B5 A17-H-B5 A18-H-B5 A19-H-B5 A20-H-B5 A21-H-B5 A15-H-B6 A16-H-B6 A17-H-B6 A18-H-B6 A19-H-B6 A20-H-B6 A21-H-B6 A15-H-B7 A16-H-B7 A17-H-B7 A18-H-B7 A19-H-B7 A20-H-B7 A21-H-B7 A15-H-B8 A16-H-B8 A17-H-B8 A18-H-B8 A19-H-B8 A20-H-B8 A21-H-B8 A15-H-B9 A16-H-B9 A17-H-B9 A18-H-B9 A19-H-B9 A20-H-B9 A21-H-B9 A15-H-B10 A16-H-B10 A17-H-B10 A18-H-B10 A19-H-B10 A20-H-B10 A21-H-B10 A15-H-B11 A16-H-B11 A17-H-B11 A18-H-B11 A19-H-B11 A20-H-B11 A21-H-B11 A15-H-B12 A16-H-B12 A17-H-B12 A18-H-B12 A19-H-B12 A20-H-B12 A21-H-B12 A15-H-B13 A16-H-B13 A17-H-B13 A18-H-B13 A19-H-B13 A20-H-B13 A21-H-B13 A15-H-B14 A16-H-B14 A17-H-B14 A18-H-B14 A19-H-B14 A20-H-B14 A21-H-B14 A15-H-B15 A16-H-B15 A17-H-B15 A18-H-B15 A19-H-B15 A20-H-B15 A21-H-B15 A22-H-B1 A23-H-B1 A24-H-B1 A25-H-B1 A26-H-B1 A27-H-B1 A28-H-B1 A22-H-B2 A23-H-B2 A24-H-B2 A25-H-B2 A26-H-B2 A27-H-B2 A28-H-B2 A22-H-B3 A23-H-B3 A24-H-B3 A25-H-B3 A26-H-B3 A27-H-B3 A28-H-B3 A22-H-B4 A23-H-B4 A24-H-B4 A25-H-B4 A26-H-B4 A27-H-B4 A28-H-B4 A22-H-B5 A23-H-B5 A24-H-B5 A25-H-B5 A26-H-B5 A27-H-B5 A28-H-B5 A22-H-B6 A23-H-B6 A24-H-B6 A25-H-B6 A26-H-B6 A27-H-B6 A28-H-B6 A22-H-B7 A23-H-B7 A24-H-B7 A25-H-B7 A26-H-B7 A27-H-B7 A28-H-B7 A22-H-B8 A23-H-B8 A24-H-B8 A25-H-B8 A26-H-B8 A27-H-B8 A28-H-B8 A22-H-B9 A23-H-B9 A24-H-B9 A25-H-B9 A26-H-B9 A27-H-B9 A28-H-B9 A22-H-B10 A23-H-B10 A24-H-B10 A25-H-B10 A26-H-B10 A27-H-B10 A28-H-B10 A22-H-B11 A23-H-B11 A24-H-B11 A25-H-B11 A26-H-B11 A27-H-B11 A28-H-B11 A22-H-B12 A23-H-B12 A24-H-B12 A25-H-B12 A26-H-B12 A27-H-B12 A28-H-B12 A22-H-B13 A23-H-B13 A24-H-B13 A25-H-B13 A26-H-B13 A27-H-B13 A28-H-B13 A22-H-B14 A23-H-B14 A24-H-B14 A25-H-B14 A26-H-B14 A27-H-B14 A28-H-B14 A22-H-B15 A23-H-B15 A24-H-B15 A25-H-B15 A26-H-B15 A27-H-B15 A28-H-B15 A29-H-B1 A30-H-B1 A31-H-B1 A32-H-B1 A33-H-B1 A34-H-B1 A35-H-B1 A29-H-B2 A30-H-B2 A31-H-B2 A32-H-B2 A33-H-B2 A34-H-B2 A35-H-B2 A29-H-B3 A30-H-B3 A31-H-B3 A32-H-B3 A33-H-B3 A34-H-B3 A35-H-B3 A29-H-B4 A30-H-B4 A31-H-B4 A32-H-B4 A33-H-B4 A34-H-B4 A35-H-B4 A29-H-B5 A30-H-B5 A31-H-B5 A32-H-B5 A33-H-B5 A34-H-B5 A35-H-B5 A29-H-B6 A30-H-B6 A31-H-B6 A32-H-B6 A33-H-B6 A34-H-B6 A35-H-B6 A29-H-B7 A30-H-B7 A31-H-B7 A32-H-B7 A33-H-B7 A34-H-B7 A35-H-B7 A29-H-B8 A30-H-B8 A31-H-B8 A32-H-B8 A33-H-B8 A34-H-B8 A35-H-B8 A29-H-B9 A30-H-B9 A31-H-B9 A32-H-B9 A33-H-B9 A34-H-B9 A35-H-B9 A29-H-B10 A30-H-B10 A31-H-B10 A32-H-B10 A33-H-B10 A34-H-B10 A35-H-B10 A29-H-B11 A30-H-B11 A31-H-B11 A32-H-B11 A33-H-B11 A34-H-B11 A35-H-B11 A29-H-B12 A30-H-B12 A31-H-B12 A32-H-B12 A33-H-B12 A34-H-B12 A35-H-B12 A29-H-B13 A30-H-B13 A31-H-B13 A32-H-B13 A33-H-B13 A34-H-B13 A35-H-B13 A29-H-B14 A30-H-B14 A31-H-B14 A32-H-B14 A33-H-B14 A34-H-B14 A35-H-B14 A29-H-B15 A30-H-B15 A31-H-B15 A32-H-B15 A33-H-B15 A34-H-B15 A35-H-B15 A36-H-B1 A37-H-B1 A38-H-B1 A39-H-B1 A40-H-B1 A41-H-B1 A42-H-B1 A36-H-B2 A37-H-B2 A38-H-B2 A39-H-B2 A40-H-B2 A41-H-B2 A42-H-B2 A36-H-B3 A37-H-B3 A38-H-B3 A39-H-B3 A40-H-B3 A41-H-B3 A42-H-B3 A36-H-B4 A37-H-B4 A38-H-B4 A39-H-B4 A40-H-B4 A41-H-B4 A42-H-B4 A36-H-B5 A37-H-B5 A38-H-B5 A39-H-B5 A40-H-B5 A41-H-B5 A42-H-B5 A36-H-B6 A37-H-B6 A38-H-B6 A39-H-B6 A40-H-B6 A41-H-B6 A42-H-B6 A36-H-B7 A37-H-B7 A38-H-B7 A39-H-B7 A40-H-B7 A41-H-B7 A42-H-B7 A36-H-B8 A37-H-B8 A38-H-B8 A39-H-B8 A40-H-B8 A41-H-B8 A42-H-B8 A36-H-B9 A37-H-B9 A38-H-B9 A39-H-B9 A40-H-B9 A41-H-B9 A42-H-B9 A36-H-B10 A37-H-B10 A38-H-B10 A39-H-B10 A40-H-B10 A41-H-B10 A42-H-B10 A36-H-B11 A37-H-B11 A38-H-B11 A39-H-B11 A40-H-B11 A41-H-B11 A42-H-B11 A36-H-B12 A37-H-B12 A38-H-B12 A39-H-B12 A40-H-B12 A41-H-B12 A42-H-B12 A36-H-B13 A37-H-B13 A38-H-B13 A39-H-B13 A40-H-B13 A41-H-B13 A42-H-B13 A36-H-B14 A37-H-B14 A38-H-B14 A39-H-B14 A40-H-B14 A41-H-B14 A42-H-B14 A36-H-B15 A37-H-B15 A38-H-B15 A39-H-B15 A40-H-B15 A41-H-B15 A42-H-B15 A43-H-B1 A44-H-B1 A45-H-B1 A46-H-B1 A47-H-B1 A48-H-B1 A49-H-B1 A43-H-B2 A44-H-B2 A45-H-B2 A46-H-B2 A47-H-B2 A48-H-B2 A49-H-B2 A43-H-B3 A44-H-B3 A45-H-B3 A46-H-B3 A47-H-B3 A48-H-B3 A49-H-B3 A43-H-B4 A44-H-B4 A45-H-B4 A46-H-B4 A47-H-B4 A48-H-B4 A49-H-B4 A43-H-B5 A44-H-B5 A45-H-B5 A46-H-B5 A47-H-B5 A48-H-B5 A49-H-B5 A43-H-B6 A44-H-B6 A45-H-B6 A46-H-B6 A47-H-B6 A48-H-B6 A49-H-B6 A43-H-B7 A44-H-B7 A45-H-B7 A46-H-B7 A47-H-B7 A48-H-B7 A49-H-B7 A43-H-B8 A44-H-B8 A45-H-B8 A46-H-B8 A47-H-B8 A48-H-B8 A49-H-B8 A43-H-B9 A44-H-B9 A45-H-B9 A46-H-B9 A47-H-B9 A48-H-B9 A49-H-B9 A43-H-B10 A44-H-B10 A45-H-B10 A46-H-B10 A47-H-B10 A48-H-B10 A49-H-B10 A43-H-B11 A44-H-B11 A45-H-B11 A46-H-B11 A47-H-B11 A48-H-B11 A49-H-B11 A43-H-B12 A44-H-B12 A45-H-B12 A46-H-B12 A47-H-B12 A48-H-B12 A49-H-B12 A43-H-B13 A44-H-B13 A45-H-B13 A46-H-B13 A47-H-B13 A48-H-B13 A49-H-B13 A43-H-B14 A44-H-B14 A45-H-B14 A46-H-B14 A47-H-B14 A48-H-B14 A49-H-B14 A43-H-B15 A44-H-B15 A45-H-B15 A46-H-B15 A47-H-B15 A48-H-B15 A49-H-B15 A50-H-B1 A51-H-B1 A52-H-B1 A53-H-B1 A54-H-B1 A55-H-B1 A56-H-B1 A50-H-B2 A51-H-B2 A52-H-B2 A53-H-B2 A54-H-B2 A55-H-B2 A56-H-B2 A50-H-B3 A51-H-B3 A52-H-B3 A53-H-B3 A54-H-B3 A55-H-B3 A56-H-B3 A50-H-B4 A51-H-B4 A52-H-B4 A53-H-B4 A54-H-B4 A55-H-B4 A56-H-B4 A50-H-B5 A51-H-B5 A52-H-B5 A53-H-B5 A54-H-B5 A55-H-B5 A56-H-B5 A50-H-B6 A51-H-B6 A52-H-B6 A53-H-B6 A54-H-B6 A55-H-B6 A56-H-B6 A50-H-B7 A51-H-B7 A52-H-B7 A53-H-B7 A54-H-B7 A55-H-B7 A56-H-B7 A50-H-B8 A51-H-B8 A52-H-B8 A53-H-B8 A54-H-B8 A55-H-B8 A56-H-B8 A50-H-B9 A51-H-B9 A52-H-B9 A53-H-B9 A54-H-B9 A55-H-B9 A56-H-B9 A50-H-B10 A51-H-B10 A52-H-B10 A53-H-B10 A54-H-B10 A55-H-B10 A56-H-B10 A50-H-B11 A51-H-B11 A52-H-B11 A53-H-B11 A54-H-B11 A55-H-B11 A56-H-B11 A50-H-B12 A51-H-B12 A52-H-B12 A53-H-B12 A54-H-B12 A55-H-B12 A56-H-B12 A50-H-B13 A51-H-B13 A52-H-B13 A53-H-B13 A54-H-B13 A55-H-B13 A56-H-B13 A50-H-B14 A51-H-B14 A52-H-B14 A53-H-B14 A54-H-B14 A55-H-B14 A56-H-B14 A50-H-B15 A51-H-B15 A52-H-B15 A53-H-B15 A54-H-B15 A55-H-B15 A56-H-B15 A57-H-B1 A58-H-B1 A59-H-B1 A60-H-B1 A61-H-B1 A62-H-B1 A63-H-B1 A57-H-B2 A58-H-B2 A59-H-B2 A60-H-B2 A61-H-B2 A62-H-B2 A63-H-B2 A57-H-B3 A58-H-B3 A59-H-B3 A60-H-B3 A61-H-B3 A62-H-B3 A63-H-B3 A57-H-B4 A58-H-B4 A59-H-B4 A60-H-B4 A61-H-B4 A62-H-B4 A63-H-B4 A57-H-B5 A58-H-B5 A59-H-B5 A60-H-B5 A61-H-B5 A62-H-B5 A63-H-B5 A57-H-B6 A58-H-B6 A59-H-B6 A60-H-B6 A61-H-B6 A62-H-B6 A63-H-B6 A57-H-B7 A58-H-B7 A59-H-B7 A60-H-B7 A61-H-B7 A62-H-B7 A63-H-B7 A57-H-B8 A58-H-B8 A59-H-B8 A60-H-B8 A61-H-B8 A62-H-B8 A63-H-B8 A57-H-B9 A58-H-B9 A59-H-B9 A60-H-B9 A61-H-B9 A62-H-B9 A63-H-B9 A57-H-B10 A58-H-B10 A59-H-B10 A60-H-B10 A61-H-B10 A62-H-B10 A63-H-B10 A57-H-B11 A58-H-B11 A59-H-B11 A60-H-B11 A61-H-B11 A62-H-B11 A63-H-B11 A57-H-B12 A58-H-B12 A59-H-B12 A60-H-B12 A61-H-B12 A62-H-B12 A63-H-B12 A57-H-B13 A58-H-B13 A59-H-B13 A60-H-B13 A61-H-B13 A62-H-B13 A63-H-B13 A57-H-B14 A58-H-B14 A59-H-B14 A60-H-B14 A61-H-B14 A62-H-B14 A63-H-B14 A57-H-B15 A58-H-B15 A59-H-B15 A60-H-B15 A61-H-B15 A62-H-B15 A63-H-B15 A64-H-B1 A65-H-B1 A66-H-B1 A67-H-B1 A68-H-B1 A69-H-B1 A70-H-B1 A64-H-B2 A65-H-B2 A66-H-B2 A67-H-B2 A68-H-B2 A69-H-B2 A70-H-B2 A64-H-B3 A65-H-B3 A66-H-B3 A67-H-B3 A68-H-B3 A69-H-B3 A70-H-B3 A64-H-B4 A65-H-B4 A66-H-B4 A67-H-B4 A68-H-B4 A69-H-B4 A70-H-B4 A64-H-B5 A65-H-B5 A66-H-B5 A67-H-B5 A68-H-B5 A69-H-B5 A70-H-B5 A64-H-B6 A65-H-B6 A66-H-B6 A67-H-B6 A68-H-B6 A69-H-B6 A70-H-B6 A64-H-B7 A65-H-B7 A66-H-B7 A67-H-B7 A68-H-B7 A69-H-B7 A70-H-B7 A64-H-B8 A65-H-B8 A66-H-B8 A67-H-B8 A68-H-B8 A69-H-B8 A70-H-B8 A64-H-B9 A65-H-B9 A66-H-B9 A67-H-B9 A68-H-B9 A69-H-B9 A70-H-B9 A64-H-B10 A65-H-B10 A66-H-B10 A67-H-B10 A68-H-B10 A69-H-B10 A70-H-B10 A64-H-B11 A65-H-B11 A66-H-B11 A67-H-B11 A68-H-B11 A69-H-B11 A70-H-B11 A64-H-B12 A65-H-B12 A66-H-B12 A67-H-B12 A68-H-B12 A69-H-B12 A70-H-B12 A64-H-B13 A65-H-B13 A66-H-B13 A67-H-B13 A68-H-B13 A69-H-B13 A70-H-B13 A64-H-B14 A65-H-B14 A66-H-B14 A67-H-B14 A68-H-B14 A69-H-B14 A70-H-B14 A64-H-B15 A65-H-B15 A66-H-B15 A67-H-B15 A68-H-B15 A69-H-B15 A70-H-B15

EXAMPLE 1 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylic acid 2-phenylethylamide

3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2,4,5,7-tetrahydropyrazolo-[3,4-c]pyridine-6-carboxylic acid 2-phenylethylamide can be prepared in the following way:

10 mg of 3-(5,6-dimethyl-1H-benzimidazol-2-yl)-2,4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine are suspended in 0.3 ml of tetrahydrofuran. 78 μl of 2-phenylethyl isocyanate are added and the reaction mixture is stirred at ambient temperature for 20 hours and then concentrated under reduced pressure.

The evaporation residue is purified by LC/MS (method B). After purification by LC/MS, the fractions containing the 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-2,4,5,7-tetrahydropyrazolo[3,4-c]pyridine-6-carboxylic acid 2-phenyl-ethylamide are combined and loaded onto SCX phase (500 mg of CUBCX1-HL phase). The SCX phase is subsequently washed with methanol and then extracted with a solution of 2M ammonia in methanol. The extraction solution obtained is then concentrated under reduced pressure. 1.2 mg of 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-2,4,5,7-tetrahydropyrazolo[3,4-c]-pyridine-6-carboxylic acid 2-phenylethylamide are thus obtained in the form of a white powder, the characteristics of which are as follows:

LC/MS (method A): molecular ion detected: 415.29; retention time=3.48 minutes.

EXAMPLE 2 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-6-methanesulphonyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine

3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-6-methanesulphonyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine can be prepared in the following way:

10 mg of 3-(5,6-dimethyl-1H-benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine are suspended in 0.3 ml of dichloromethane. 15.8 μl of triethylamine are added, along with 4.5 μl of methanesulphonyl chloride. The reaction mixture is stirred at ambient temperature for 20 hours and is then concentrated under reduced pressure.

The evaporation residue is purified by LC/MS (method B). After purification by LC/MS, the fractions containing 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-6-methanesulphonyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine are combined and loaded onto SCX phase (500 mg of CUBCX1-HL phase). The SCX phase is subsequently washed with methanol and then extracted with a solution of 2M ammonia in methanol. The extraction solution obtained is then concentrated under reduced pressure. 4.2 mg of 3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-6-methanesulphonyl-4,5,6,7-tetrahydro-2H-pyrazolo-[3,4-c]pyridine are thus obtained in the form of a white powder, the characteristics of which are as follows:

-   LC/MS (method A): molecular ion detected: 346.30; retention     time=3.08 minutes. -   ¹H NMR (300 MHz, (CD₃)₂SO, δ in ppm): 2.32 (broad s: 6H); 3.02 (s:     3H); 3.03 (mt: 2H); 3.52 (broad t, J=5 Hz: 2H); 4.45 (broad s: 2H);     7.24 (broad s: 1H); 7.42 (broad s: 1H); 12.45 (unresolved peak: 1H);     13.07 (unresolved peak: 1H).

EXAMPLE 3 [3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridin-6-yl]-3-pyridinylmethanone

[3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)-2,4,5,7-tetrahydropyrazolo-[3,4-c]pyridin-6-yl]-3-pyridinylmethanone can be prepared in the following way:

10 mg of 3-(5,6-dimethyl-1H-benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine are suspended in 0.3 ml of DMF. 6.9 mg of nicotinic acid are added, followed by 7.6 mg of HOBT and 8.7 μl of diisopropylcarbo-diimide.

The reaction mixture is stirred at ambient temperature for 20 hours and is then concentrated under reduced pressure.

The evaporation residue is purified by LC/MS (method B). After purification by LC/MS, the fractions containing the [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-2,4,5,7-tetrahydropyrazolo[3,4-c]pyridin-6-yl]-3-pyridinylmethanone are combined and loaded onto SCX phase (500 mg of CUBCX1-HL phase). The SCX phase is subsequently washed with methanol and then extracted with a solution of 2M ammonia in methanol. The extraction solution obtained is then concentrated under reduced pressure. 5.3 mg of [3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-2,4,5,7-tetrahydropyrazolo[3,4-c]pyridin-6-yl]-3-pyridinyl-methanone are thus obtained in the form of a white powder, the characteristics of which are as follows:

-   LC/MS (method A): molecular ion detected: 373.31; retention     time=2.87 minutes -   ¹H NMR (400 MHz, (CD₃)₂SO, at a temperature of 373K, 6 in ppm): 2.35     (s: 6H); from 2.90 to 3.10 (mt: 2H); 3.76 (unresolved peak: 2H);     4.76 (broad s: 2H); 7.27 (unresolved peak: 1H); 7.40 (unresolved     peak: 1H); 7.51 (dd, J=8 and 5 Hz: 1H); 7.90 (broad d, J=8 Hz: 1H);     8.70 (mt: 2H); from 11.80 to 12.20 (broad unresolved peak: 1H); from     12.50 to 13.00 (broad unresolved peak: 1H).

EXAMPLE 4 6-(3-Chlorobenzyl)-3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine

6-(3-Chlorobenzyl)-3-(5,6-dimethyl-1H-benzoimidazol-2-yl)4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine can be prepared in the following way:

10 mg of 3-(5,6-dimethyl-1H-benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine are suspended in 0.3 ml of methanol. 12.7 μl of 3-chlorobenzaldehyde are added, followed by 4.7 mg of NaBH₃CN. The reaction mixture is stirred at ambient temperature for 20 hours and is then concentrated under reduced pressure.

The evaporation residue is purified by LC/MS (method B). After purification by LC/MS, the fractions containing the 6-(3-chlorobenzyl)-3-(5,6-dimethyl-1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine are combined and loaded onto a SCX phase (500 mg of CUBCX1-HL phase). The SCX phase is subsequently washed with methanol and then extracted with a solution of 2M ammonia in methanol. The extraction solution obtained is then concentrated under reduced pressure. 4 mg of 6-(3-chlorobenzyl)-3-(5,6-dimethyl-1H-benzoimidazol-2-yl)4,5,6,7-tetrahydro-2H-pyrazolo-[3,4-c]pyridine are thus obtained in the form of a white powder, the characteristics of which are as follows:

-   LC/MS (method A): molecular ion detected: 392.26; retention time     3.18 minutes. -   ¹H NMR (400 MHz, (CD₃)₂SO, at a temperature of 373K, 67 in ppm):     2.35 and 2.36 (2 s: 6H in total); 2.83 (t, J=5.5 Hz: 2H); from 2.90     to 3.00 (mt: 2H); 3.62 (broad s: 2H); 3.78 (s: 2H); from 7.25 to     7.50 (mt: 6H); 11.91 (unresolved peak: 1H); from 12.30 to 12.60     (broad unresolved peak: 1H).

EXAMPLE 5 [3-(1H-Benzoimidazol-2-yl)-2,4,5,7-tetrahydropyrazolo[3,4-c]-pyridin-6-yl]-3-pyridinylmethanone

[3-(1H-Benzoimidazol-2-yl)-2,4,5,7-tetrahydropyrazolo[3,4-c]pyridin-6-yl]-3-pyridinylmethanone can be prepared in the following way:

15 mg of 3-(1H-benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]-pyridine hydrochloride are suspended in 0.5 ml of DMF. 24.3 mg of diisopropylethylamine are added, followed by 12.7 mg of HOBT, 11.9 mg of diisopropylcarbodiimide and 11.6 mg of nicotinic acid. The reaction mixture is stirred at ambient temperature for 20 hours and then concentrated under reduced pressure.

The evaporation residue is purified by LC/MS (method B). After purification by LC/MS, the fractions containing the [3-(1H-benzoimidazol-2-yl)-2,4,5,7-tetrahydropyrazolo[3,4-c]pyridin-6-yl]-3-pyridinylmethanone are combined and loaded onto SCX phase (500 mg of CUBCX1-HL phase). The SCX phase is subsequently washed with methanol and then extracted with a solution of 2M ammonia in methanol. The extraction solution obtained is then concentrated under reduced pressure. 7.7 mg of [3-(1H-benzoimidazol-2-yl)-2,4,5,7-tetrahydropyrazolo[3,4-c]pyridin-6-yl]-3-pyridinylmethanone are thus obtained in the form of a white powder, the characteristics of which are as follows:

-   LC/MS (method A): molecular ion detected: 345.22; retention     time=1.95 minutes.

EXAMPLE 6 6-(3-Chlorobenzyl)-3-(1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine

6-(3-Chlorobenzyl)-3-(1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine can be prepared in the following way:

15 mg of 3-(1H-benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]-pyridine hydrochloride are suspended in 0.5 ml of methanol. 26.5 mg of 3-chlorobenzaldehyde are added, followed by 7.9 mg of NaBH₃CN. The reaction mixture is stirred at ambient temperature for 20 hours and is then concentrated under reduced pressure.

The evaporation residue is purified by LC/MS (method B). After purification by LC/MS, the fractions containing the 6-(3-chlorobenzyl)-3-(1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine are combined and loaded onto SCX phase (500 mg of CUBCX1-HL phase). The SCX phase is subsequently washed with methanol and extracted with a solution of 2M ammonia in methanol. The extraction solution obtained is then concentrated under reduced pressure. 6.9 mg of 6-(3-chlorobenzyl)-3-(1H-benzoimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine are thus obtained in the form of a white powder, the characteristics of which are as follows:

-   LC/MS (method A): molecular ion detected: 364.22; retention     time=2.19 minutes.

EXAMPLE 7 Preparation of an Amide Library

The amide library can be prepared in the following way:

The 19 acids (Table 4) are weighed and placed in 19 individual test tubes. TABLE 4 Acids used Entry Name Amount 1 ISOBUTYRIC ACID 3.3 mg 2 BENZOIC ACID 4.6 mg 3 2,3-DICHLOROBENZOIC ACID 7.1 mg 4 PHENYLACETIC ACID 5.1 mg 5 ACETIC ACID 2.2 mg 6 CYCLOPROPANECARBOXYLIC ACID 3.2 mg 7 2-CHLOROBENZOIC ACID 5.9 mg 8 3-CHLOROBENZOIC ACID 5.9 mg 9 4-CHLOROBENZOIC ACID 5.9 mg 10 ISOVALERIC ACID 3.8 mg 11 HYDROCINNAMIC ACID 5.6 mg 12 VINYLACETIC ACID 3.2 mg 13 BUTYRIC ACID 3.3 mg 14 2-FUROIC ACID 4.2 mg 15 PIVALIC ACID 3.8 mg 16 N,N-DIMETHYLGLYCINE 3.9 mg 17 VALERIC ACID 3.8 mg 18 THIOPHENE-2-CARBOXYLIC ACID 4.8 mg 19 4-METHYLSULPHONYLBENZOIC ACID 7.5 mg 152 mg of HOBT and 142 mg of diisopropylcarbodiimide are solubilized in 12 ml of DMF and the solution obtained is distributed in each of the 19 test tubes, at a rate of 600 μl per tube.

200 mg of 3-(5,6-dimethyl-1H-benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine hydrochloride are suspended in 4 ml of DMF in the presence of 290 mg of N,N-diisopropylethylamine, and the suspension obtained is distributed into each of the 19 test tubes, at a rate of 200 μl per tube.

The 19 reaction mixtures are shaken by means of orbital shaking at ambient temperature for 20 hours.

For each reaction mixture, a 10 μl sample is taken and diluted in 40 μl of DMSO (Gilson Liquid Handler Quad-Z 215). Each sample in solution in DMSO thus obtained is analysed by LC/MS (method A).

The 19 reaction mixtures are then evaporated to dryness and the evaporation residues are each solubilized in 500 μl of DMSO, and the solutions obtained are then purified by LC/MS (method B).

After purification by LC/MS, the fractions containing the desired compounds are (optionally combined) loaded onto SCX phase (500 mg of CUBCX1-HL phase). The SCX phases are subsequently washed with methanol and then extracted with a solution of 2M ammonia in methanol. The extraction solutions are collected in tared glass tubes, evaporated to dryness (Savant AES 2000 or Genevac HT8 centrifugal evaporator), weighed (Mettler Toledo Automated Workstation LA200) and diluted to 10 mM in DMSO (Gilson Liquid Handler Quad-Z 215). Each solution obtained is analysed by LC/MS (method A).

The following compounds (Table 5) were isolated and characterized by means of their retention time and molecular peak in mass spectrometry (method A). TABLE 5 Amide library obtained Amount of Retention Molecular product time ion Entry Name obtained (minutes) detected 1 1-[3-(5,6-Dimethyl-1H-benzoimidazol- 5.8 mg 3.08 338.23 2-yl)-2,4,5,7-tetrahydropyrazolo- [3,4-c]pyridin-6-yl]-2-methylpropan-1- one 2 [3-(5,6-Dimethyl-1H-benzoimidazol-2- 6.8 mg 2.68 372.21 yl)-2,4,5,7-tetrahydropyrazolo[3,4-c]- pyridin-6-yl]phenylmethanone 3 (2,3-Dichlorophenyl)-[3-(5,6-dimethyl- 12 mg 3.05 440.13 1H-benzoimidazol-2-yl)-2,4,5,7- tetrahydropyrazolo[3,4-c]pyridin-6-yl]- methanone 4 1-[3-(5,6-Dimethyl-1H-benzoimidazol- 7.9 mg 2.99 386.23 2-yl)-2,4,5,7-tetrahydropyrazolo- [3,4-c]pyridin-6-yl]-2-phenylethanone 5 1-[3-(5,6-Dimethyl-1H-benzoimidazol- 2.7 mg 2.4 310.19 2-yl)-2,4,5,7-tetrahydropyrazolo- [3,4-c]pyridin-6-yl]ethanone 6 Cyclopropyl-[3-(5,6-dimethyl-1H- 3.4 mg 2.57 336.21 benzoimidazol-2-yl)-2,4,5,7- tetrahydropyrazolo[3,4-c]pyridin-6-yl]- methanone 7 (2-Chlorophenyl)-[3-(5,6-dimethyl-1H- 11.2 mg 2.97 406.18 benzoimidazol-2-yl)-2,4,5,7- tetrahydropyrazolo[3,4-c]pyridin-6-yl]- methanone 8 (3-Chlorophenyl)-[3-(5,6-dimethyl-1H- 12.1 mg 3.31 406.16 benzoimidazol-2-yl)-2,4,5,7- tetrahydropyrazolo[3,4-c]pyridin-6-yl]- methanone 9 (4-Chlorophenyl)-[3-(5,6-dimethyl-1H- 11.5 mg 3.51 406.17 benzoimidazol-2-yl)-2,4,5,7- tetrahydropyrazolo[3,4-c]pyridin-6-yl]- methanone 10 1-[3-(5,6-Dimethyl-1H-benzoimidazol- 4.8 mg 2.72 352.24 2-yl)-2,4,5,7-tetrahydropyrazolo[3,4-c]- pyridin-6-yl]-3-methylbutan-1-one 11 1-[3-(5,6-Dimethyl-1H-benzoimidazol- 11.9 mg 2.95 400.24 2-yl)-2,4,5,7-tetrahydropyrazolo[3,4-c]- pyridin-6-yl]-3-phenylpropan-1-one 12 1-[3-(5,6-Dimethyl-1H-benzoimidazol- 10.1 mg 2.72 336.22 2-yl)-2,4,5,7-tetrahydropyrazolo- [3,4-c]pyridin-6-yl]but-3-en-1-one 13 1-[3-(5,6-Dimethyl-1H-benzoimidazol- 7 mg 2.66 338.23 2-yl)-2,4,5,7-tetrahydropyrazolo- [3,4-c]pyridin-6-yl]butan-1-one 14 [3-(5,6-Dimethyl-1H-benzoimidazol-2- 9.5 mg 2.67 362.19 yl)-2,4,5,7-tetrahydropyrazolo[3,4-c]- pyridin-6-yl]furan-2-yl-methanone 15 1-[3-(5,6-Dimethyl-1H-benzoimidazol- 9.3 mg 2.8 352.24 2-yl)-2,4,5,7-tetrahydropyrazolo[3,4-c]- pyridin-6-yl]-2,2-dimethylpropan-1-one 16 2-Dimethylamino-1-[3-(5,6-dimethyl- 4.7 mg 2.55 353.23 1H-benzoimidazol-2-yl)-2,4,5,7- tetrahydro-pyrazolo[3,4-c]pyridin-6- yl]ethanone 17 1-[3-(5,6-Dimethyl-1H-benzoimidazol- 5.4 mg 2.78 352.24 2-yl)-2,4,5,7-tetrahydropyrazolo[3,4-c]- pyridin-6-yl]pentan-1-one 18 [3-(5,6-Dimethyl-1H-benzoimidazol-2- 7.2 mg 2.75 378.17 yl)-2,4,5,7-tetrahydropyrazolo[3,4-c]- pyridin-6-yl]thiophen-2-yl-methanone 19 [3-(5,6-Dimethyl-1H-benzoimidazol-2- 14.3 mg 2.79 450.19 yl)-2,4,5,7-tetrahydropyrazolo[3,4-c]- pyridin-6-yl]-(4-methanesulphonyl- phenyl)methanone

EXAMPLE 8 Preparation of a Sulphonamide Library

The sulphonamide library can be prepared in the following way:

190 mg of 3-(5,6-dimethyl-1H-benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine hydrochloride are suspended in 2 ml of dichloromethane in the presence of 150 μl of triethylamine, and the suspension obtained is distributed into 17 test tubes, at a rate of 500 μl per tube. The 17 sulphonyl chlorides (Table 6) are weighed and added to each of the 17 test tubes. TABLE 6 Sulphonyl chlorides used Entry Name Quantity 1 BENZENESULPHONYL CHLORIDE 9.9 mg 2 ALPHA-TOLUENESULPHONYL 10.7 mg CHLORIDE 3 2,3-DICHLOROBENZENE- 13.8 mg SULPHONYL CHLORIDE 4 4-CHLOROBENZENESULPHONYL 11.9 mg CHLORIDE 5 2,2,2-TRIFLUOROETHANE- 10.2 mg SULPHONYL CHLORIDE 6 ETHANESULPHONYL CHLORIDE 7.2 mg 7 1-PROPANESULPHONYL CHLORIDE 8 mg 8 1-BUTANESULPHONYL CHLORIDE 8.8 mg 9 2-CHLOROBENZENESULPHONYL 11.9 mg CHLORIDE 10 3-CHLOROBENZENESULPHONYL 11.9 mg CHLORIDE 11 [(4-FLUOROPHENYL)METHYL]- 11.7 mg SULPHONYL CHLORIDE 12 4-METHOXYBENZENESULPHONYL 11.6 mg CHLORIDE 13 P-TOLUENESULPHONYL CHLORIDE 10.7 mg 14 O-TOLUENESULPHONYL CHLORIDE 10.7 mg 15 3-METHYLBENZENESULPHONYL 10.7 mg CHLORIDE 16 3-METHOXYBENZENESULPHONYL 11.6 mg CHLORIDE 17 2-METHOXY-4-METHYLBENZENE- 12.4 mg SULPHONYL CHLORIDE

The 17 reaction mixtures are shaken by means of orbital shaking at ambient temperature for 20 h.

For each reaction mixture, a 10 μl sample is taken and diluted in 40 μl of DMSO (Gilson Liquid Handler Quad-Z 215). Each sample in solution in DMSO thus obtained is analysed by LC/MS (method A).

The 17 reaction mixtures are then evaporated to dryness and the evaporation residues are each solubilized in 1 ml of DMSO in the presence of a drop of an aqueous 5N hydrochloric acid solution, and the solutions obtained are purified by LC/MS (method B). After purification by LC/MS, the fractions containing the desired compounds are (optionally combined) loaded onto SCX phase (500 mg of CUBCX1-HL phase). The SCX phases are subsequently washed with methanol and then extracted with a solution of 2M ammonia in methanol. The extraction solutions are collected in tared glass tubes, evaporated to dryness (Savant AES 2000 or Genevac HT8 centrifugal evaporator), weighed (Mettler Toledo Automated Workstation LA200) and diluted to 10 mM in DMSO (Gilson Liquid Handler Quad-Z 215). Each solution obtained is analysed by LC/MS (method A).

The following compounds (Table 7) were isolated and characterized by means of their retention time and molecular peak in mass spectrometry (method A). TABLE 7 Sulphonamide library obtained Amount Retention Molecular of product time ion Entry Name obtained (minutes) detected 1 6-Benzenesulphonyl-3-(5,6-dimethyl- 1.4 mg 3.41 408.18 1H-benzoimidazol-2-yl)-4,5,6,7- tetrahydro-2H-pyrazolo[3,4-c]pyridine 2 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)- 0.7 mg 3.51 422.2 6-phenylmethanesulphonyl-4,5,6,7- tetrahydro-2H-pyrazolo[3,4-c]pyridine 3 6-(2,3-Dichlorobenzenesulphonyl)-3- 6.4 mg 3.25 476.1 (5,6-dimethyl-1H-benzoimidazol-2-yl)- 4,5,6,7-tetrahydro-2H-pyrazolo- [3,4-c]pyridine 4 6-(4-Chlorobenzenesulphonyl)-3-(5,6- 5.9 mg 3.19 442.12 dimethyl-1H-benzoimidazol-2-yl)- 4,5,6,7-tetrahydro-2H-pyrazolo- [3,4-c]pyridine 5 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)- 1.7 mg 3.06 414.14 6-(2,2,2-trifluoroethanesulphonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo- [3,4-c]pyridine 6 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)- 5.2 mg 2.63 360.17 6-ethanesulphonyl-4,5,6,7-tetrahydro- 2H-pyrazolo[3,4-c]pyridine 7 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)- 4.3 mg 2.8 374.19 6-(propane-1-sulphonyl)-4,5,6,7- tetrahydro-2H-pyrazolo[3,4-c]pyridine 8 6-(Butane-1-sulphonyl)-3-(5,6-dimethyl- 5.6 mg 2.94 388.2 1H-benzoimidazol-2-yl)-4,5,6,7- tetrahydro-2H-pyrazolo[3,4-c]pyridine 9 6-(2-Chlorobenzenesulphonyl)-3-(5,6- 5.6 mg 3.38 442.13 dimethyl-1H-benzoimidazol-2-yl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]- pyridine 10 6-(3-Chlorobenzenesulphonyl)-3-(5,6- 6.9 mg 3.71 442.13 dimethyl-1H-benzoimidazol-2-yl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]- pyridine 11 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)- 0.7 mg 3.05 440.18 6-(4-fluorophenylmethanesulphonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]- pyridine 12 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)- 7.5 mg 2.99 438.19 6-(4-methoxybenzenesulphonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]- pyridine 13 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)- 7.3 mg 3.22 422.2 6-(toluene-4-sulphonyl)-4,5,6,7- tetrahydro-2H-pyrazolo[3,4-c]pyridine 14 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)- 4.8 mg 3.16 422.19 6-(toluene-2-sulphonyl)-4,5,6,7- tetrahydro-2H-pyrazolo[3,4-c]pyridine 15 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)- 5.1 mg 3.13 422.19 6-(toluene-3-sulphonyl)-4,5,6,7- tetrahydro-2H-pyrazolo[3,4-c]pyridine 16 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)- 6.9 mg 3.07 438.18 6-(3-methoxybenzenesulphonyl)- 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]- pyridine 17 3-(5,6-Dimethyl-1H-benzoimidazol-2-yl)- 0.8 mg 3.34 452.19 6-(2-methoxy-4-methyl-benzene- sulphonyl)-4,5,6,7-tetrahydro-2H- pyrazolo[3,4-c]pyridine

EXAMPLE 9 Preparation of an Amine Library

The amine library can be prepared in the following way:

180 mg of 3-(5,6-dimethyl-1H-benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine hydrochloride are suspended in 2.7 ml of methanol and the suspension obtained is distributed into 16 test tubes, at a rate of 150 μl per tube.

The 16 aldehyde (Table 8) are weighed and added to each of the 16 test tubes. TABLE 8 Aldehydes used Entry Name Quantity 1 ISOBUTYRALDEHYDE 8.1 mg 2 FORMALDEHYDE 3.4 mg 3 BENZALDEHYDE 11.9 mg 4 PHENYLACETALDEHYDE 13.5 mg 5 2,3-DICHLOROBENZALDEHYDE 19.6 mg 6 FURFURAL 10.8 mg 7 4-CHLOROBENZALDEHYDE 15.8 mg 8 2-THIOPHENECARBOXALDEHYDE 12.6 mg 9 NICOTINALDEHYDE 12 mg 10 TRIMETHYLACETALDEHYDE 9.7 mg 11 ACETALDEHYDE 4.9 mg 12 ISOVALERALDEHYDE 9.7 mg 13 PROPIONALDEHYDE 6.5 mg 14 3-PHENYLPROPIONALDEHYDE 15.1 mg 15 BUTYRALDEHYDE 8.1 mg 16 CYCLOPROPANECARBOXALDEHYDE 7.9 mg

A solution of 85 mg of NaBH₃CN in 2.7 ml of methanol is then also distributed into the 16 test tubes, at a rate of 150 μl per tube. The 16 reaction mixtures are shaken by means of orbital shaking at ambient temperature for 20 h. 100 μl of methanol are then added to each of the 16 tubes.

For each reaction mixture, a 10 μl sample is taken and diluted in 40 μl of DMSO (Gilson Liquid Handler Quad-Z 215). Each sample in solution in DMSO thus obtained is analysed by LC/MS (method A).

The 16 reaction mixtures are then evaporated to dryness and the evaporation residues are each solubilized in 500 μl of DMSO and filtered through sintered glass, and the residual solutions are then purified by LC/MS (method B). After purification by LC/MS, the fractions containing the desired compounds are (optionally combined) loaded onto SCX phase (500 mg of CUBCX1-HL phase). The SCX phases are subsequently washed with methanol and then extracted with a solution of 2M ammonia in methanol. The extraction solutions are collected in tared glass tubes, evaporated to dryness (Savant AES 2000 or Genevac HT8 centrifugal evaporator), weighed (Mettler Toledo Automated Workstation LA200) and diluted to 10 mM in DMSO (Gilson Liquid Handler Quad-Z 215). Each solution obtained is analysed by LC/MS (method A).

The following compounds (Table 9) were isolated and characterized by means of their retention time and molecular peak in mass spectrometry (method A). TABLE 9 Amine library obtained Amount of Retention Molecular product time ion Entry Name obtained (minutes) detected 1 3-(5,6-Dimethyl-1H-benzoimidazol-2- 5.9 mg 2.62 324.32 yl)-6-isobutyl-4,5,6,7-tetrahydro-2H- pyrazolo[3,4-c]pyridine 2 3-(5,6-Dimethyl-1H-benzoimidazol-2- 3.5 mg 2.49 282.29 yl)-6-methyl-4,5,6,7-tetrahydro-2H- pyrazolo[3,4-c]pyridine 3 6-Benzyl-3-(5,6-dimethyl-1H-benzo- 8.2 mg 2.74 358.3 imidazol-2-yl)-4,5,6,7-tetrahydro-2H- pyrazolo[3,4-c]pyridine 4 3-(5,6-Dimethyl-1H-benzoimidazol-2- 6.4 mg 2.84 372.32 yl)-6-phenethyl-4,5,6,7-tetrahydro-2H- pyrazolo[3,4-c]pyridine 5 6-(2,3-Dichlorobenzyl)-3-(5,6-dimethyl- 8.6 mg 2.95 426.23 1H-benzoimidazol-2-yl)-4,5,6,7- tetrahydro-2H-pyrazolo[3,4-c]pyridine 6 3-(5,6-Dimethyl-1H-benzoimidazol-2- 5.9 mg 2.64 348.27 yl)-6-furan-2-ylmethyl-4,5,6,7- tetrahydro-2H-pyrazolo[3,4-c]pyridine 7 6-(4-Chlorobenzyl)-3-(5,6-dimethyl-1H- 4.7 mg 2.9 392.26 benzoimidazol-2-yl)-4,5,6,7-tetrahydro- 2H-pyrazolo[3,4-c]pyridine 8 3-(5,6-Dimethyl-1H-benzoimidazol-2- 8.4 mg 2.71 364.24 yl)-6-thiophen-2-ylmethyl-4,5,6,7- tetrahydro-2H-pyrazolo[3,4-c]pyridine 9 3-(5,6-Dimethyl-1H-benzoimidazol-2- 11.7 mg 2.55 359.29 yl)-6-pyridin-3-ylmethyl-4,5,6,7- tetrahydro-2H-pyrazolo[3,4-c]pyridine 10 3-(5,6-Dimethyl-1H-benzoimidazol-2- 3.7 mg 2.72 338.32 yl)-6-(2,2-dimethylpropyl)-4,5,6,7- tetrahydro-2H-pyrazolo[3,4-c]pyridine 11 3-(5,6-Dimethyl-1H-benzoimidazol-2- 5 mg 2.55 296.27 yl)-6-ethyl-4,5,6,7-tetrahydro-2H- pyrazolo[3,4-c]pyridine 12 3-(5,6-Dimethyl-1H-benzoimidazol-2- 5.9 mg 2.76 338.3 yl)-6-(3-methylbutyl)-4,5,6,7-tetrahydro- 2H-pyrazolo[3,4-c]pyridine 13 3-(5,6-Dimethyl-1H-benzoimidazol-2- 6.4 mg 2.62 310.29 yl)-6-propyl-4,5,6,7-tetrahydro-2H- pyrazolo[3,4-c]pyridine 14 3-(5,6-Dimethyl-1H-benzoimidazol-2- 4.2 mg 2.97 386.31 yl)-6-(3-phenylpropyl)-4,5,6,7- tetrahydro-2H-pyrazolo[3,4-c]pyridine 15 6-Butyl-3-(5,6-dimethyl-1H-benzo- 4.5 mg 2.68 324.28 imidazol-2-yl)-4,5,6,7-tetrahydro-2H- pyrazolo[3,4-c]pyridine 16 6-Cyclopropylmethyl-3-(5,6-dimethyl- 3.9 mg 2.62 322.27 1H-benzoimidazol-2-yl)-4,5,6,7- tetrahydro-2H-pyrazolo[3,4-c]pyridine

EXAMPLE 10 Preparation of a Urea Library

The urea library can be prepared in the following way:

120 mg of 3-(5,6-dimethyl-1H-benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine hydrochloride are suspended in 3.6 ml of tetrahydrofuran in the presence of 190 μl of triethylamine, and the suspension obtained is distributed into each of the 9 test tubes, at a rate of 300 μl per tube.

The 9 isocyanates (Table 10) are weighed and added to each of the 9 test tubes. TABLE 10 Isocyanates used Entry Name Amount 1 PHENYL ISOCYANATE 6.7 mg 2 BENZYL ISOCYANATE 7.5 mg 3 2-CHLOROPHENYL ISOCYANATE 8.6 mg 4 3-CHLOROPHENYL ISOCYANATE 8.6 mg 5 4-CHLOROPHENYL ISOCYANATE 8.6 mg 6 N-BUTYL ISOCYANATE 5.6 mg 7 2-THIENYL ISOCYANATE   7 mg 8 2-METHOXYPHENYL ISOCYANATE 8.4 mg 9 O-TOLYL ISOCYANATE 7.5 mg

The 9 reaction mixtures are shaken by means of orbital shaking at ambient temperature for 2 hours, and are then evaporated to dryness.

Evaporation residues are each solubilized in 1 ml of DMSO and, for each solution obtained, a 10 μl sample is taken and diluted in 40 μl of DMSO (Gilson Liquid Handler Quad-X 215). Each sample in solution in DMSO thus obtained is analysed by LC/MS (method A).

The residual solutions are purified by LC/MS (method B). After purification by LC/MS, the fractions containing the desired compounds are (optionally combined) either evaporated to dryness (entries 1, 3, 6, 8 and 9) or loaded onto SCX phase (500 mg of CUBCX1-HL phase; entries 2, 4, 5 and 7). The SCX phases are subsequently washed with methanol and then extracted with a solution of 2M ammonia in methanol. The extraction solutions are collected in tared glass tubes, evaporated to dryness (Savant AES 2000 or Genevac HT8 centrifugal evaporator), weighed (Mettler Toledo Automated Workstation LA200) and diluted to 10 mM in DMSO (Gilson Liquid Handler Quad-Z 215). Each solution obtained is analysed by LC/MS (method A).

The following compounds (Table 11) were isolated and characterized by means of their retention time and molecular peak in mass spectrometry (method A). TABLE 11 Urea library obtained Amount of Retention Molecular product time ion Entry Name obtained (minutes) detected 1 3-(5,6-Dimethyl-1H-benzoimidazol-2- 14.6 mg 3.04 387.28 yl)-2,4,5,7-tetrahydropyrazolo[3,4-c]- pyridine-6-carboxylic acid phenyl- amide bistrifluoroacetate 2 3-(5,6-Dimethyl-1H-benzoimidazol-2- 1.8 mg 2.78 401.29 yl)-2,4,5,7-tetrahydropyrazolo- [3,4-c]pyridine-6-carboxylic acid benzylamide 3 3-(5,6-Dimethyl-1H-benzoimidazol-2- 16 mg 2.92 421.25 yl)-2,4,5,7-tetrahydropyrazolo- [3,4-c]pyridine-6-carboxylic acid (2-chlorophenyl)amide bistrifluoro- acetate 4 3-(5,6-Dimethyl-1H-benzoimidazol-2- 7.9 mg 3.89 421.24 yl)-2,4,5,7-tetrahydropyrazolo- [3,4-c]pyridine-6-carboxylic acid (3-chlorophenyl)amide 5 3-(5,6-Dimethyl-1H-benzoimidazol-2- 9.8 mg 3.36 421.25 yl)-2,4,5,7-tetrahydropyrazolo- [3,4-c]pyridine-6-carboxylic acid (4-chlorophenyl)amide 6 3-(5,6-Dimethyl-1H-benzoimidazol-2- 2.4 mg 2.8 367.31 yl)-2,4,5,7-tetrahydropyrazolo- [3,4-c]pyridine-6-carboxylic acid butylamide bistrifluoroacetate 7 3-(5,6-Dimethyl-1H-benzoimidazol-2- 3.8 mg 2.77 393.24 yl)-2,4,5,7-tetrahydropyrazolo- [3,4-c]pyridine-6-carboxylic acid thiophen-2-ylamide 8 3-(5,6-Dimethyl-1H-benzoimidazol-2- 14.4 mg 3.14 417.28 yl)-2,4,5,7-tetrahydropyrazolo- [3,4-c]pyridine-6-carboxylic acid (2-methoxyphenyl)amide bistrifluoroacetate 9 3-(5,6-Dimethyl-1H-benzoimidazol-2- 16.2 mg 2.68 401.29 yl)-2,4,5,7-tetrahydropyrazolo- [3,4-c]pyridine-6-carboxylic acid o-tolylamide bistrifluoroacetate

EXAMPLE 11 3-(5,6-Dimethyl-1H-benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine

3-(5,6-Dimethyl-1H-benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo-[3,4-c]pyridine can be prepared in the following way:

9 ml of water and 2.8 ml of trifluoroacetic acid are added to a solution of 670 mg of tert-butyl 3-(2-amino-4,5-dimethylphenylcarbamoyl)-2,4,5,7-tetrahydropyrazolo[3,4-c]pyridine-6-carboxylate in 9 ml of THF. After stirring for 2 hours at 80° C., the reaction medium is concentrated under reduced pressure. It is then taken up in water and the precipitate formed is recovered by filtration through sintered glass, washed with an aqueous 1N sodium hydroxide solution and dried. The aqueous phase obtained is subsequently extracted with dichloromethane and the organic phase is then dried over magensium sulphate and concentrated under reduced pressure. The residue obtained and the precipitate are combined and then solubilized in methanol with a few drops of DMF. This solution is then loaded onto MEGA BE-SCX phase. The SCX phase is subsequently washed with methanol and extracted with a solution of 2M ammonia in methanol. The extraction solution obtained is then concentrated under reduced pressure.

46 mg of 3-(5,6-dimethyl-1H-benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine are thus obtained in the form of a beige powder, the characteristics of which are as follows: El: m/z = 267 M^(+.) base peak m/z = 238 [M − NHCH₂]⁺ m/z = 209 [M − C₃H₈N]^(+.)

¹H NMR (300 MHz, (CD₃)₂SO, δ in ppm): 2.31 and 2.32 (2 s: 6H in total); 2.81 (broad t, J=5 Hz: 2H); 2.92 (broad t, J=5 Hz: 2H); 3.83 (broad s: 2H); 7.22 (broad s: 1H); 7.40 (broad s: 1H); 12.28 (unresolved peak: 1H); 12.73 (unresolved peak: 1H).

EXAMPLE 12 3-(5,6-Dimethyl-1H-benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine hydrochloride

3-(5,6-Dimethyl-1H-benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine can be prepared in the following way:

9 ml of an aqueous 5N hydrochloric acid solution are added to a solution of 1.7 g of tert-butyl 3-(2-amino-4,5-dimethylphenylcarbamoyl)-2,4,5,7-tetrahydropyrazolo[3,4-c]pyridine-6-carboxylate in 40 ml of ethanol. After stirring at 80° C. for 60 hours, the reaction medium is brought back to ambient temperature. The precipitate formed is recovered by filtration through sintered glass and dried. 1.04 g of 3-(5,6-dimethyl-1H-benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine hydrochloride are thus obtained in the form of a beige powder, the characteristics of which are as follows: El: m/z = 267 M^(+.) base peak m/z = 238 [M − CH₂NH]⁺ m/z = 209 [M − C₃H₈N]^(+.) m/z = 36 [HCl]⁺

¹H NMR (300 MHz, (CD₃)₂SO with addition of a few drops of CD₃COOD, δ in ppm): 2.40 (s: 6H); 3.23 (broad t, J=5.5 Hz: 2H); 3.45 (t, J=5.5 Hz: 2H); 4.45 (s: 2H); 7.54 (s: 2H).

tert-Butyl 3-(2-amino-4,5-dimethylphenylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylate can be prepared in the following way: 8.5 g of HBTU and also 2.9 g of diisopropylethylamine are added, at ambient temperature, to a solution of 3 g of (tert-butyl 2,4,5,7-tetrahydropyrazolo-[3,4-c]pyridine-6-carboxylate)-3-carboxylic acid in 50 ml of anhydrous DMF. After twenty minutes' stirring at ambient temperature, 3.06 g of 4,5-diamino-o-xylene are added. After stirring at ambient temperature for 60 hours, the reaction medium is diluted in 3 l of an aqueous NaHCO₃ solution at pH greater than 7, containing 20 g of NaCl. The aqueous phase is extracted three times with 1 l of ethyl acetate, and the combined organic phases are then dried over magnesium sulphate and concentrated under reduced pressure. The crude residue obtained is taken up in 150 ml of dichloromethane and the insoluble material is removed by filtration through sintered glass. The filtrate is then concentrated under reduced pressure and purified by chromatography on silica (20-45 μm Amicon) with a gradient of from 50 to 100% of ethyl acetate in cyclohexane. The fractions containing the desired product are combined and concentrated under reduced pressure. 4.37 g of tert-butyl 3-(2-aminophenylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylate are thus obtained in the form of a beige powder, the characteristics of which are as follows: El: m/z = 385 M^(+.) base peak m/z = 329 [M − C₄H₈]^(+.) m/z = 312 [M − C₄H₉O]⁺ m/z = 57 [C₄H₉]⁺

¹H NMR (300 MHz, (CD₃)₂SO, δ in ppm): 1.46 (s: 9H); 2.10 and 2.12 (2 s: 3H each); 2.77 (mt: 2H); 3.58 (t, J=5.5 Hz: 2H); 4.53 (s: 2H); 4.57 (unresolved peak: 2H); 6.60 (s: 1H); 7.14 (broad s: 1H); 9.10 (unresolved peak: 1H); 13.08 (unresolved peak: 1H).

EXAMPLE 13 3-(1H-Benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo-[3,4-c]pyridine Hydrochloride

3-(1H-Benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine hydrochloride can be prepared in the following way:

2.2 ml of an aqueous 5N hydrochloric acid solution are added to a solution of 200 mg of tert-butyl 3-(2-aminophenylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylate in 1 ml of ethanol. After stirring for 20 hours at 80° C., the reaction medium is brought back to ambient temperature. The insoluble material is removed by filtration through sintered glass and the filtrate is concentrated under reduced pressure. 84 mg of 3-(1H-benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine hydrochloride are thus obtained in the form of an orange-coloured powder, the characteristics of which are as follows:

-   LC/MS (method A): molecular ion detected: 240.26; retention     time=1.68 minutes -   tert-Butyl     3-(2-aminophenylcarbamoyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]-pyridine-6-carboxylate     can be prepared in the following way:

425 mg of HBTU and also 145 mg of diisopropylethylamine are added, at ambient temperature, to a solution of 150 mg of (tert-butyl 2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridine-6-carboxylate)-3-carboxylic acid in 1 ml of anhydrous DMF. After stirring for twenty minutes at ambient temperature, 121 mg of orthophenylenediamine are added.

After stirring at ambient temperature for 20 hours, the reaction medium is diluted in 100 ml of water and 50 ml of ethyl acetate. The aqueous phase is extracted three times with 50 ml of ethyl acetate and the combined organic phases are then dried over magnesium sulphate and concentrated under reduced pressure. The crude residue obtained is purified by HPLC (reverse phase C18 Lichroprep 12 μm) with a linear gradient of from 5 to 95% of acetonitrile comprising 0.07% (v/v) of trifluoroacetic acid in water comprising 0.07% (v/v) of trifluoroacetic acid, at a flow rate of 10 ml/min. The fractions containing the desired product are combined and loaded onto MEGA BE-SCX phase. The SCX phase is subsequently washed with methanol and extracted with a solution of 2M ammonia in methanol. The extraction solution obtained is then concentrated under reduced pressure. 200 mg of tert-butyl 3-(2-aminophenylcarbamoyl)-2,4,5,7-tetrahydropyrazolo[3,4-c]pyridine-6-carboxylate are thus obtained in the form of a beige powder, the characteristics of which are as follows:

-   LC/MS (method A): molecular ion detected: 358.34; retention     time=3.19 minutes.

EXAMPLE 14 Preparation of a Sulphonamide Library

The sulphonamide library can be prepared in the following way:

40 mg of 6-[3-(5,6-dimethyl-1H-benzimidazol-2-yl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridin-6-yl]pyridin-3-ylamine are suspended in 2 ml of dichloromethane and the solution obtained is distributed into 4 test tubes, at a rate of 500 μl per tube.

The 4 sulphonyl chlorides (Table 12) are weighed and added to each of the 4 test tubes, followed by 15.6 μl of triethylamine. TABLE 12 Sulphonyl chlorides used Entry Name Amount 1 THIOPHENE-2-SULPHONYL CHLORIDE 5.6 mg 2 4-METHOXYBENZENESULPHONYL CHLORIDE 6.3 mg 3 2-CHLOROBENZENESULPHONYL CHLORIDE 6.4 mg 4 2-METHOXY-4-METHYLBENZENESULPHONYL 6.8 mg CHLORIDE

The 4 reaction mixtures are shaken by means of orbital shaking at 40° C. for 15 h.

For each reaction mixture, a 5 μl sample is taken and diluted in 100 μl of DMSO (Gilson Liquid Handler Quad-Z 215). Each sample in solution in DMSO thus obtained is analysed by LC/MS (method A).

The 4 reaction mixtures are then evaporated to dryness and the evaporation residues are each solubilized in 500 μl of DMSO and the solutions obtained are purified by LC/MS (method B). After purification by LC/MS, the fractions containing the desired compounds are (optionally combined) loaded onto SCX phase (500 mg of CUBCX1-HL phase). The SCX phases are subsequently washed with methanol and then extracted with a solution of 2M ammonia in methanol. The extraction solutions are collected in tared glass tubes, evaporated to dryness (Savant AES 2000 or Genevac HT8 centrifugal evaporator), weighed (Mettler Toledo Automated Workstation LA200) and diluted to 10 mM in DMSO (Gilson Liquid Handler Quad-Z 215). Each solution obtained is analysed by LC/MS (method A).

The following compounds (Table 13) were isolated and characterized by means of their retention time and molecular peak in mass spectrometry (method A) TABLE 13 Sulphonamide library obtained Amount Retention Molecular of product time ion Entry Name obtained (minutes) detected 1 N-{6-[3-(5,6-Dimethyl-1H- 2.9 mg 3.07 506.21 benzimidazol-2-yl)-2,4,5,7- tetrahydropyrazolo[3,4-c]pyridin- 6-yl]pyridin-3-yl}thiophene-2- sulphonamide 2 N-{6-[3-(5,6-Dimethyl-1H- 3.0 mg 3.20 530.25 benzimidazol-2-yl)-2,4,5,7- tetrahydropyrazolo[3,4-c]pyridin- 6-yl]pyridin-3-yl}-4-methoxy- benzenesulphonamide 3 2-Chloro-N-{6-[3-(5,6-dimethyl- 3.0 mg 3.38 534.21 1H-benzimidazol-2-yl)-2,4,5,7- tetrahydropyrazolo[3,4-c]pyridin- 6-yl]pyridin-3-yl}benzene- sulphonamide 4 N-{6-[3-(5,6-Dimethyl-1H- 3.8 mg 3.38 544.26 benzimidazol-2-yl)-2,4,5,7- tetrahydropyrazolo[3,4-c]pyridin- 6-yl]pyridin-3-yl}-2-methoxy-4- methylbenzenesulphonamide

EXAMPLE 15 6-[3-(5,6-Dimethyl-1H-benzimidazol-2-yl)-2,4,5,7-tetrahydro-pyrazolo[3,4-c]pyridin-6-yl]pyridin-3-ylamine

6-[3-(5,6-Dimethyl-1H-benzimidazol-2-yl)-2,4,5,7-tetrahydropyrazolo-[3,4-c]pyridin-6-yl]pyridin-3-ylamine can be prepared in the following way:

55 mg of Pd/CaCO₃10% are added to a solution of 545 mg of 3-(5,6-dimethyl-1H-benzimidazol-2-yl)-6-(5-nitropyridin-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine in 60 ml of ethanol. After stirring for 15 hours at 35° C. under 3 bar of hydrogen, the reaction medium is brought back to ambient temperature, filtered through celite and then concentrated under reduced pressure. 300 mg of 6-[3-(5,6-dimethyl-1H-benzimidazol-2-yl)-2,4,5,7-tetrahydropyrazolo[3,4-c]pyridin-6-yl]-pyridin-3-ylamine are thus obtained in the form of a brown powder, the characteristics of which are as follows:

-   EI m/z=359 M^(+.) base peak     -   m/z=266 (M-C₅H₅N₂)⁺

EXAMPLE 16 3-(5,6-Dimethyl-1H-benzimidazol-2-yl)-6-(5-nitropyridin-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine

3-(5,6-Dimethyl-1H-benzimidazol-2-yl)-6-(5-nitropyridin-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine can be prepared in the following way:

287 mg of 2-chloro-5-nitropyridine and 500 mg of potassium carbonate are added to a solution of 500 mg of 3-(5,6-dimethyl-1H-benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine hydrochloride in 5 ml of dimethylformamide. After stirring for 20 hours at ambient temperature, the reaction medium is added to 50 ml of water. The precipitate formed is recovered by filtration through sintered glass, washed with 3 times 15 ml of water and then dried under reduced pressure. 548 mg of 3-(5,6-dimethyl-1H-benzimidazol-2-yl)-6-(5-nitropyridin-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo-[3,4-c]pyridine are thus obtained in the form of a yellow powder, the characteristics of which are as follows: El: m/z = 389 M^(+.) base peak m/z = 266 (M − C₅H₃N₂O₂)⁺

EXAMPLE 17 6-{5-[3-(2-Fluoro-5-trifluoromethylphenyl)ureido]pyridin-2-yl}-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxamide

6-{5-[3-(2-Fluoro-5-trifluoromethylphenyl)ureido]pyridin-2-yl}-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxamide can be prepared in the following way from ethyl 6-(5-tert-butoxycarbonylaminopyridin-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylate:

The ethyl ester of ethyl 6-(5-tert-butoxycarbonylaminopyridin-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylate is converted to carboxamide by amidation using a solution of aqueous ammonia, and results in the obtaining of 6-(5-tert-butoxycarbonylaminopyridin-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxamide.

-   EI: m/z=358

The amine group of the 6-(5-tert-butoxycarbonylaminopyridin-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxamide is deprotected in acid medium (trifluoroacetic acid in dichloromethane) and results in the obtaining of 6-(5-aminopyridin-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxamide.

-   EI: m/z=258

The urea function is introduced onto the 6-(5-aminopyridin-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxamide according to the method described in Example 1, using 2-fluoro-5-(trifluoromethyl)phenyl isocyanate, and results in the obtaining of 6-{5-[3-(2-fluoro-5-trifluoromethylphenyl)-ureido]pyridin-2-yl}4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carb-oxamide.

-   EI: m/z=463

EXAMPLE 18 Ethyl 6-(5-tert-butoxycarbonylaminopyridin-2-yl)-4,5,6,7-tetra-hydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylate

Ethyl 6-(5-tert-butoxycarbonylaminopyridin-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylate can be prepared in the following way:

5 mg of Pd/C 10% and 38 mg of di-tert-butyl dicarbonate are added to a solution of 50 mg of ethyl 6-(5-nitropyridin-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylate in 6 ml of methanol. After stirring for 12 hours at ambient temperature under 3 bar of hydrogen, the reaction medium is filtered through celite and then concentrated under reduced pressure. The reaction crude obtained is purified by flash chromatography (SiO₂, CH₂Cl₂/MeOH gradient 75/25 to 25/75). 20 mg of ethyl 6-(5-tert-butoxycarbonylaminopyridin-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylate are thus obtained in the form of a white powder, the characteristics of which are as follows: El: m/z = 387 M^(+.) m/z = 331 (M − C₄H₈)^(+.) base peak m/z = 286 (m/z = 331 − CO₂H)⁺ m/z = 194 C₉H₁₂N₃O₂₊ m/z = 57 C₄H₉ ⁺

EXAMPLE 19 Ethyl 6-(5-nitropyridin-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo [3,4-c]pyridine-3-carboxylate

Ethyl 6-(5-nitropyridin-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylate can be prepared in the following way:

522 mg of 2-chloro-5-nitropyridine are added to a solution of 1 g of 3-(5,6-dimethyl-1H-benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine trifluoroacetate in 10 ml of pyridine. After stirring for 20 hours at ambient temperature, the reaction medium is concentrated under reduced pressure. The precipitate formed is recovered by filtration through sintered glass, washed with 3 times 15 ml of water, and dried under reduced pressure. The reaction crude obtained is purified by flash chromatography (SiO₂, cyclohexane/EtOAc gradient 75/25 to 25/75). 450 mg of ethyl 6-(5-nitro-pyridin-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylate are thus obtained in the form of a yellow powder, the characteristics of which are as follows: El: m/z = 317 M^(+.) base peak m/z = 271 (M − NO₂)^(+.) m/z = 194 (M − C₅H₃N₂O₂)⁺ m/z = 148 (m/z = 194 − C₂H₆O)⁺

EXAMPLE 20 Ethyl 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylate Trifluoroacetate

Ethyl 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylate trifluoro-acetate can be prepared in the following way:

50 ml of water followed by 12 ml of trifluoroacetic acid are added to a solution of 3 g of 6-tert-butyl-3-ethyl 2,4,5,7-tetrahydropyrazolo[3,4-c]pyridyl-3,6-dicarboxylate in 50 ml of tetrahydrofuran. After stirring for 2 hours at reflux, the reaction medium is brought back to ambient temperature and a saturated aqueous Na₂CO₃ solution is added until a basic pH is obtained. The aqueous phase obtained is extracted 3 times with ethyl acetate. The combined organic phases are dried over magnesium sulphate and concentrated under reduced pressure. 1.49 g of ethyl 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine-3-carboxylate trifluoroacetate are thus obtained, the characteristics of which are as follows: El: m/z = 195 M^(+.) m/z = 166 (M − CH₃N)^(+.) base peak m/z = 138 (M − C₃H₇N)^(+.) m/z = 120 (m/z = 166 − C₂H₆O)^(+.) m/z = 92 (m/z = 120 − CO)^(+.) Measurements of the Inhibitory Potential of the Products with Respect to the Activity of the tie2 and kdr Kinases:

The inhibitory activity of the products with respect to the Tie2 and KDR kinases is tested according to the experimental protocols described below.

1. Tie2

The coding sequence of human Tie2 corresponding to amino acids 776-1124 of the intracellular domain was generated by PCR using the cDNA isolated from human placenta as model. This sequence was introduced into a baculovirus expression vector pFastBacGT in the form of a GST fusion protein.

The inhibitory effect of the molecules is determined in an assay for phosphorylation of PLC by Tie2 in the presence of GST-Tie2 purified to approximately 80% homogeneity. The substrate is made up of the SH2-SH3 fragments of PLC, the latter being expressed in the form of a GST fusion protein.

The kinase activity of Tie2 is measured in a 20 mM MOPS buffer, pH 7.2, containing 10 mM MgCl₂, 10 mM MnCl₂, 1 mM DTT and 10 mM of glycerophosphate. A reaction mixture made up of 70 μl of kinase buffer containing 100 ng of GST-Tie2 enzyme per well is placed in a flashplate 96-well plate kept on ice. 10 μl of the molecule to be tested, diluted in DMSO, at a concentration of at most 10% are then added. For a given concentration, each measurement is carried out in quadruplicate. The reaction is initiated by adding 20 μl of solution containing 2 μg of GST-PLC, 2 μM of cold ATP and 1 μCi of ³³P[ATP]. After incubation for 1 hour at 37° C., the reaction is stopped by adding 1 volume (100 μl) of 200 mM EDTA. After removal of the incubation buffer, the wells are washed three times with 300 μl of PBS. The radioactivity is measured on a Wallac MicroBeta 1450.

The inhibition of the Tie2 activity is calculated and expressed as percentage inhibition with respect to the control activity determined in the absence of compound.

2. KDR

The inhibitory effect of the compounds is determined in an assay for phosphorylation of substrate by the KDR enzyme in vitro using a scintillation technique (96-well plate, NEN).

The cytoplasmic domain of the human KDR enzyme was cloned in GST fusion form into the baculovirus expression vector pFastBac. The protein was expressed in SF21 cells and purified to approximately 60% homogeneity.

The KDR kinase activity is measured in 20 mM MOPS, 10 mM MgCl₂, 10 mM MnCl₂, 1 mM DTT, 2.5 mM EGTA, 10 mM b-glycerophosphate, pH=7.2, in the presence of 10 mM MgCl₂, 100 μM Na₃VO₄ and 1 mM NaF. 10 μl of the compound are added to 70 μl of kinase buffer containing 100 ng of KDR enzyme at 4° C. The reaction is initiated by adding 20 μl of solution containing 2 μg of substrate (SH2-SH3 fragment of PLCy expressed in the form of an GST fusion protein), 2 μCi γ ³³P[ATP] and 2 μM cold ATP. After incubation for 1 hour at 37° C., the reaction is stopped by adding 1 volume (100 μl) of 200 mM EDTA. The incubation buffer is removed and the wells are washed three times with 300 μl of PBS. The radioactivity is measured in each well using a Top Count NXT (Packard) radioactivity counter.

The background noise is determined by measuring the radioactivity in four different wells containing the radioactive ATP and the substrate alone.

A total activity control is measured in four different wells containing all the reagents (γ³³P-[ATP], KDR and PLC-γ substrate) but in the absence of compound.

The inhibition of the KDR activity with the compound of the invention is expressed as percentage inhibition of the control activity determined in the absence of compound.

The compound SU5614 (Calbiochem) (1 μM) is included in each plate as inhibition control.

Results: Tie2 KDR % Inhib at 10 μM (FRX) % Inhib at 10 μM Chemistry Assay 1 Assay 2 Assay 1 Assay 2 P-31378-112-3 78.7 79.1 59.0 56.5

P-31378-112-6 92.7 93.8 71.4 68.0

P-31378-112-2 92.6 92.6 98.1 97.4

P-31378-112-8^(H) 87.8 93.3 86.8 89.0

P-31378-112-4 83.1 87.2 56.2 50.1

P-31378-112-9 82.6 85.9 53.2 45.1

P-31378-112-14 69.7 73.8 19.5 13.0

P-31378-1 12-1 83.1 88.1 96.5 96.7

P-31378-112-16 88.7 88.3 90.2 89.1

P-31378-112-5 87.1 86.4 94.7 95.4

P-31378-112-10 90.6 87.9 42.3 28.7

P-31378-112-7 92.7 92.0 68.6 64.3

P-31378-112-15 80.1 83.8 75.5 77.4

KDR % Inhib. Tie2 % Inhib. Chemistry 10 μM 10 μM

77.20 Chemistry 2

78.10 Chemistry 3

25.40 Chemistry 4

88.80 Chemistry 5

2.10 41.2 Chemistry 6

12.15 48.6 Chemistry 7

85.45 64.3 Chemistry 8

15.45 56.7 Chemistry 9

79.55 83.9 Chemistry 10

70.35 66.1 Chemistry 11

69.05 60.3 Chemistry 12

84.50 41.5 Chemistry 13

14.85 50.5 Chemistry 14

39.30 69.4 Chemistry 15

−5.75 36.4 Chemistry 16

−2.90 50.7 Chemistry 17

−3.70 55.0 Chemistry 18

17.90 68.1 Chemistry 19

1.65 47.6 Chemistry 20

1.85 33.0 Chemistry 21

3.65 24.9 Chemistry 22

48 92.5 Chemistry 23

70.75 91.5 Chemistry 24

31.85 89.1 Chemistry 25

27.75 89.1 Chemistry 26

22.95 65.4 Chemistry 27

16.50 78.5 Chemistry 28

13.35 47.5 Chemistry 29

15.30 44.2 Chemistry 30

45.70 93.2 Chemistry 31

46.45 91.5 Chemistry 32

57.70 95.9 Chemistry 33

18.15 84.7 Chemistry 34

27.40 88.8 Chemistry 35

49.40 90.8 Chemistry 36

41.20 88.3 Chemistry 37

20.85 84.6 Chemistry 38

30.90 97.9 Chemistry 39

14.40 83.4 Chemistry 40

72.50 86.3 Chemistry 41

52.65 97.4 Chemistry 42

10.90 84.4 Chemistry 43

41.10 90.8 Chemistry 44

33.40 94.1 Chemistry 45

73.05 96.7 Chemistry 46

78.55 87.7 Chemistry 47

41.95 83.8 Chemistry 48

12.20 84.8 Chemistry 49

74.75 82.4 Chemistry 50

38.70 72.9 Chemistry 51

29.35 89.3 Chemistry 52

74.55 92.7 Chemistry 53

11.25 81.3 Chemistry 54

15.95 65.4 Chemistry 55

46.65 92.5 Chemistry 56

75.15 94.6 Chemistry 57

27.90 82.3 Chemistry 58

17.6 33.2 Chemistry 59

33.55 64.85 Chemistry 60

12.7 3.75 Chemistry 61

12.85 21 Chemistry 62

−0.3 23.75 Chemistry 63

18 38.5 Chemistry 64

63.3 85.9 Chemistry 65

8.1 18.05 Chemistry 67

19.5 19.1 Chemistry 68

18.55 59.3 Chemistry 69

92.1 65.5 Chemistry 70

98

100

99

100 

1-24. (canceled)
 25. A compound of formula (I), including its tautomers:

wherein: L is chosen from a bond, CH₂, CO, SO₂, CONH, COO, NHCO, NH, NHSO₂, SO₂NH, NHCONH, CH₂NH and NHCH₂; X is chosen from a bond, CH₂, CO, SO₂, CONH and COO; R1 is OH or H, or is chosen from alkyl, cycloalkyl, heterocycle, aryl, heteroaryl, all of which is optionally substituted, and, when X is a bond, then R1 may also be halogen; R2 is H or is chosen from alkyl, alkylene, cycloalkyl, heterocycle, aryl, heteroaryl, all of which is optionally substituted; and in that the optional substituents are chosen independently from R3, O—R3, halogen, NO₂, SO₂—R3, CO—R3, SO₂NH—R3, CONH—R3, N—(R3)₂, NHCO—R3, NHSO₂—R3, NHCONH—R3, NHSO₂NH—R3, OCO—R3, COO—R3, OSO₂—R3, SO₂O—R3, OCONH—R3 and OSO₂NH—R3, wherein R3 is H or is chosen independently from alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, heterocycle, all of which is optionally substituted with halogen, aryl, heteroaryl, R4, OR4 or N(R4)₂, wherein each R4 is chosen independently from H, C₁-C₄ alkyl and halogenated C₁-C₄ alkyl, or a racemate, a stereoisomer, an enantiomer, or a mixture in any combination thereof, or a pharmaceutically acceptable salt thereof.
 26. The compound as set forth in claim 25, which is of the formula (II):

And its tautomers, wherein: X is chosen from a bond, CH₂, CO, SO₂, CONH and COO; R1 is chosen from alkyl, cycloalkyl, heterocycle, aryl, heteroaryl, all of which is optionally substituted; R2 is H or is chosen from alkyl, alkylene, cycloalkyl, heterocycle, aryl, heteroaryl, all of which is optionally substituted; and in that the optional substituents are chosen independently from R3, O—R3, halogen, NO₂, SO₂—R3, CO—R3, SO₂NH—R3, CONH—R3, N—(R3)₂, NHCO—R3, NHSO₂—R3, NHCONH—R3, NHSO₂NH—R3, OCO—R3, COO—R3, OSO₂—R3, SO₂O—R3, OCONH—R3 and OSO₂NH—R3, wherein each R3 is H or is chosen independently from alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, heterocycle, all of which is optionally substituted with halogen, aryl, heteroaryl, OR4 or N(R4)₂, in which each R4 is chosen independently from H and C₁-C₄ alkyl, or a racemate, a stereoisomer, an enantiomer, or a mixture in any combination thereof, or a pharmaceutically acceptable salt thereof.
 27. The compound as set forth in claim 25, which is of the formula (III):

and its tautomers, wherein: X is chosen from a bond, CH₂, CO, SO₂, CONH and COO; R1 is chosen from alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, all of which is optionally substituted; R2 is H or is chosen from alkyl, alkylene, cycloalkyl, heterocycle, aryl, heteroaryl, all of which is optionally substituted; and in that the optional substituents are chosen independently from R3, O—R3, halogen, NO₂, SO₂—R3, CO—R3, SO₂NH—R3, CONH—R3, N—(R3)₂, NHCO—R3, NHSO₂—R3, NHCONH—R3, NHSO₂NH—R3, OCO—R3, COO—R3, OSO₂—R3, SO₂O—R3, OCONH—R3 and OSO₂NH—R3, wherein each R3 is H or is chosen independently from alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, heterocycle, all of which is optionally substituted with halogen, aryl, heteroaryl, OR4 or N(R4)₂, and wherein each R4 is chosen independently from H and C₁-C₄ alkyl, or a racemate, a stereoisomer, an enantiomer, or a mixture in any combination thereof, or a pharmaceutically acceptable salt thereof.
 28. The compound as set forth in claim 25, wherein R1 is heteroaryl, which is optionally substituted.
 29. The compound as set forth in claim 26, wherein R1 is heteroaryl, which is optionally substituted.
 30. The compound as set forth in claim 27, wherein R1 is heteroaryl, which is optionally substituted.
 31. The compound as set forth in claim 28, wherein R1 is chosen from benzimidazolyl, indolyl, pyrrolyl, optionally substituted with halogen, R4 or O—R4, wherein R4 is chosen independently from H and C₁-C₄ alkyl.
 32. The compound as set forth in claim 31, wherein R1 is chosen from benzimidazol-2-yl, indol-2-yl, pyrrol-2-yl, optionally substituted with halogen, R4 or O—R4, wherein R4 is chosen independently from H and C₁-C₄ alkyl.
 33. The compound as set forth in claim 25, wherein R2 is chosen from phenyl, pyridyl, thienyl, C₁-C₄ alkyl, and C₃-C₇ cycloalkyl, all of which is optionally substituted.
 34. The compound as set forth in claim 25, wherein X is chosen from CO and SO₂.
 35. The compound as set forth in claim 25, wherein R1 is H.
 36. The compound as set forth in claim 25, wherein R1 is substituted aryl.
 37. The compound as set forth in claim 25, wherein R1-L is R1-NH—CO.
 38. The compound as set forth in claim 37, wherein R1 is H.
 39. The compound as set forth in claim 25, wherein X is a bond, and R2 is chosen from substituted aryl and substituted heteroaryl.
 40. The compound as set forth in claim 37, wherein X is a bond, and R2 is chosen from substituted aryl and substituted heteroaryl.
 41. The compound as set forth in claim 38, wherein X is a bond, and R2 is chosen from substituted aryl and substituted heteroaryl.
 42. The compound as set forth in claim 41, wherein R2 is chosen from: aryl substituted with NHSO₂—R3 or NHCONH—R3, and heteroaryl substituted with NHSO₂—R3 or NHCONH—R3, wherein each R3 is H or is chosen independently from alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, heterocycle, all of which is optionally substituted with halogen, aryl, heteroaryl, OR4 or N(R4)₂, and wherein each R4 is chosen independently from H, C₁-C₄ alkyl and halogenated C₁-C₄ alkyl.
 43. The compound as set forth in claim 42, wherein aryl is phenyl, and heteroaryl is chosen from pyridyl and pyrimidyl.
 44. The compound as set forth in claim 42, wherein R3 is chosen from substituted aryl and substituted heteroaryl.
 45. The compound as set forth in claim 44, wherein R3 is substituted with a substituent selected from the group consisting of halogen, R4, OR4 and N(R4)₂, wherein each R4 is chosen independently from H, C₁-C₄ alkyl and halogenated C₁-C₄ alkyl.
 46. The compound as set forth in claim 45, which is chosen from:


47. A pharmaceutical composition comprising a compound of formula (I), including its tautomers, in combination with one or more pharmaceutically acceptable excipient, diluent or a carrier:

wherein: L is chosen from a bond, CH₂, CO, SO₂, CONH, COO, NHCO, NH, NHSO₂, SO₂NH, NHCONH, CH₂NH and NHCH₂; X is chosen from a bond, CH₂, CO, SO₂, CONH and COO; R1 is OH or H, or is chosen from alkyl, cycloalkyl, heterocycle, aryl, heteroaryl, all of which is optionally substituted, and, when X is a bond, then R1 may also be halogen; R2 is H or is chosen from alkyl, alkylene, cycloalkyl, heterocycle, aryl, heteroaryl, all of which is optionally substituted; and in that the optional substituents are chosen independently from R3, O—R3, halogen, NO₂, SO₂—R3, CO—R3, SO₂NH—R3, CONH—R3, N—(R3)₂, NHCO—R3, NHSO₂—R3, NHCONH—R3, NHSO₂NH—R3, OCO—R3, COO—R3, OSO₂—R3, SO₂O—R3, OCONH—R3 and OSO₂NH—R3, wherein R3 is H or is chosen independently from alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, heterocycle, all of which is optionally substituted with halogen, aryl, heteroaryl, R4, OR4 or N(R4)₂, wherein each R4 is chosen independently from H, C₁-C₄ alkyl and halogenated C₁-C₄ alkyl, or a racemate, a stereoisomer, an enantiomer, or a mixture in any combination thereof, or a pharmaceutically acceptable salt thereof.
 48. A method of treating a pathological condition in a patient comprising administering to said patient a therapeutically effective amount of a compound of formula (I), including its tautomers, optionally in combination with one or more pharmaceutically acceptable excipient, diluent or a carrier:

wherein: L is chosen from a bond, CH₂, CO, SO₂, CONH, COO, NHCO, NH, NHSO₂, SO₂NH, NHCONH, CH₂NH and NHCH₂; X is chosen from a bond, CH₂, CO, SO₂, CONH and COO; R1 is OH or H, or is chosen from alkyl, cycloalkyl, heterocycle, aryl, heteroaryl, all of which is optionally substituted, and, when X is a bond, then R1 may also be halogen; R2 is H or is chosen from alkyl, alkylene, cycloalkyl, heterocycle, aryl, heteroaryl, all of which is optionally substituted; and in that the optional substituents are chosen independently from R3, O—R3, halogen, NO₂, SO₂—R3, CO—R3, SO₂NH—R3, CONH—R3, N—(R3)₂, NHCO—R3, NHSO₂—R3, NHCONH—R3, NHSO₂NH—R3, OCO—R3, COO—R3, OSO₂—R3, SO₂O—R3, OCONH—R3 and OSO₂NH—R3, wherein R3 is H or is chosen independently from alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, heterocycle, all of which is optionally substituted with halogen, aryl, heteroaryl, R4, OR4 or N(R4)₂, wherein each R4 is chosen independently from H, C₁-C₄ alkyl and halogenated C₁-C₄ alkyl, or a racemate, a stereoisomer, an enantiomer, or a mixture in any combination thereof, or a pharmaceutically acceptable salt thereof.
 49. The method as set forth in claim 48, wherein the compound is modulating the activity of a kinase.
 50. The method as set forth in claim 49, wherein the kinase is chosen from Tie2 and KDR.
 51. The method as set forth in claim 48, wherein the pathological condition is cancer. 